Modified uricase and uses thereof

JP2023548496A5Active Publication Date: 2024-11-08PROTALIX
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023526588
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-03
Filing Date
2021-11-03
Publication Date
2024-11-08
Estimated Expiration
2041-11-03
Patent Text Reader

Abstract

Described herein are modified uricase and methods for reducing uric acid levels by contacting a medium with the modified uricase. The modified uricase comprises a uricase polypeptide crosslinked by at least one bifunctional linking moiety comprising a poly(alkylene glycol) moiety. The bifunctional linking moiety has a molecular weight of about 1.5 kDa to about 4 kDa, and / or the modified uricase comprises a plurality of polypeptides having the amino acid sequence of SEQ ID NO: 2. Also described are polypeptides having the amino acid sequence of SEQ ID NO: 2. Also described are methods for preparing the modified uricase, comprising contacting a polypeptide with a crosslinking agent comprising a poly(alkylene glycol) moiety and at least two aldehyde groups to obtain a conjugate, and contacting the conjugate with a reducing agent.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Related Applications This application claims priority to U.S. Provisional Patent Application No. 63 / 108,890, filed November 3, 2020, the contents of which are incorporated herein by reference in their entirety.

[0002] Sequence Listing Description An ASCII file entitled 89419.txt, created on October 31, 2021, containing 11,072 bytes, filed concurrently with the filing of this application, is incorporated herein by reference.

[0003] The present invention, in some embodiments thereof, relates to therapy, and more particularly, but not exclusively, to novel forms of uricase and their uses, such as in lowering uric acid levels. [Background technology]

[0004] Uric acid is a metabolic breakdown product of purine nucleotides. High blood levels of uric acid (hyperuricemia) can cause gout and / or kidney stones, and high uric acid levels have been linked to hemorrhagic shock [D'Alessandro et al., J Transl Med 2015, 13:253], malaria [Gallego-Delgado et al., Curr Rheumatol Rep 2014, 16:401], allergic asthma [Kool et al., Immunity 2011, 34:P527-P540], traumatic brain injury [Liu et al., Int J Med Sci 2018, 15:1072-1082], renal dysfunction and acute gastroenteritis [Matsuo et al., Sci Rep 2016, 6:31003], and multiple sclerosis [Piancone et al., Front Immunol 2018, 9:983], inflammatory bowel disease [Crane & Mongiardo, Immunol Invest 2014, 43:255-266], gastrointestinal infections [Crane et al., Infect Immun 2016, 84:976-988], and other conditions including sterile inflammation and pregnancy complications [Nadeau-Vallee et al., Reproduction 2016, 152:R277-R292].

[0005] The usual first-line treatment for gout is to treat the symptoms using, for example, steroidal or nonsteroidal anti-inflammatory drugs. Additional medications include allopurinol and febuxostat, which are inhibitors of the enzyme xanthine oxidase (which produces uric acid), and probenecid, lesinurate, and benzbromarone, which are thought to inhibit the reabsorption of uric acid in the kidney.

[0006] Uricase, also known in the art as urate oxidase, is an enzyme that catalyzes the oxidation of uric acid to 5-hydroxyisouric acid (consuming O and generating HO). 5-hydroxyisouric acid is hydrolyzed to allantoin in most animals, plants, and bacteria. However, uricase is absent in humans (and some other great apes), and therefore, humans are particularly susceptible to high blood uric acid levels.

[0007] Rasburicase (commercially available as Elitek®) is a tetrameric uricase cloned from Aspergillus flavus and approved in the United States and Europe for use in the prevention and treatment of tumor lysis syndrome in subjects undergoing cancer chemotherapy. Off-label use of rasburicase to treat gout has also been reported [J Rheumatol 2007, 34:2093-2098]. Rasburicase has a half-life of 6 to 21 hours and must be administered daily by intravenous infusion.

[0008] Pegloticase (commercially available as Krystexxa®) is a PEGylated tetrameric pig-baboon chimeric uricase approved for the treatment of refractory gout. In each of the four monomers, an average of 10 of the 30 lysine residues are conjugated with 10 kDa PEG chains.

[0009] Uricase is a protein not naturally occurring in humans and therefore highly immunogenic. Both rasburicase and pegloticase can cause anaphylaxis as a severe side effect. The PEG moiety of pegloticase can reduce immune responses to the uricase backbone, but the PEG moiety itself can serve as a target for antibodies (Zhang et al., J Control Release 2016, 244:184-193; Hershfield et al., Arthritis Res Ther 2014, 16:R63; Ganson et al., Arthritis Res Ther 2006, 8:R12).

[0010] In a phase 3 clinical trial of pegloticase, 26% of patients experienced infusion reactions and 6.5% experienced reactions characterized as anaphylaxis [Baraf et al., Arthritis Res Ther 2013, 15:R137, Strand et al., J Rheumatol 2012, 39:1450-1457].

[0011] In phase 2 and 3 trials lasting up to 6 months, antibodies to pegloticase were detectable (by various methods) in more than 80% of patients at some point, with the highest titers associated with loss of efficacy and infusion reactions [Sundy et al., JAMA 2011, 306:711-720, Sundy et al., Arthritis Rheum 2008, 58:2882-2891].

[0012] WO 00 / 07629 describes uricase covalently conjugated with PEG, with an average of 2-10 PEG chains per uricase subunit and an average PEG molecular weight between about 5 kDa and 100 kDa.

[0013] WO 2011 / 107992 describes multimeric protein structures comprising monomers of a therapeutic protein such as TNF-α, luteinizing hormone, immunoglobulin, TNF-α receptor, CTLA-4, urate oxidase, VEGF, PDGF, VEGF receptor, PDGF receptor, interleukin-17 or fragments thereof, which monomers are covalently linked to each other via a linking moiety.

[0014] Koyama et al. [J Biochem 1996, 120:969-973] described Candida utilis uricase and its mutants in which cysteine ​​residues were replaced with serine residues, and concluded that of the four cysteine ​​residues, only Cys 168 is involved in enzymatic activity.

[0015] Chua et al. [Ann Intern Med 1988, 109:114-117] described Arthrobacter protoformiae uricase modified with monofunctional (methoxy-capped) PEG and reported that it did not induce antibody production for 3 weeks after administration.

[0016] Further background art includes Hershfield et al. (2009) ["Development of PEGylated mammalian urate oxidase as a therapy for patients with refractory gout," in Veronese FM (ed.) PEGylated Protein Drugs: Basic Science and Clinical Applications. Milestones in Drug Therapy, Birkhauser Basel], Nyborg et al. [PLoS ONE 2016,11:e0167935] and Veronese [Biomaterials 2001, 22:405-417], U.S. Pat. Nos. 4,179,337, 6,913,915, 8,188,224, and 9,885,024; U.S. Patent Application Publication Nos. 2007 / 0274977 and 2008 / 0159976; and WO 2011 / 107990, WO 2011 / 107991, WO 2016 / 187026, WO 2018 / 010369, and WO 2019 / 010369. Summary of the Invention

[0017] According to one aspect of some embodiments of the present invention, there is provided a modified uricase comprising a uricase polypeptide crosslinked by at least one bifunctional linking moiety comprising a poly(alkylene glycol) moiety, wherein the molecular weight of the bifunctional linking moiety ranges from about 1.5 kDa to about 4 kDa.

[0018] According to one aspect of some embodiments of the present invention, there is provided a modified uricase comprising a plurality of polypeptides having the amino acid sequence of SEQ ID NO:2, wherein the polypeptides are crosslinked by at least one bifunctional linking moiety comprising a poly(alkylene glycol) moiety.

[0019] According to an aspect of some embodiments of the present invention there is provided a polypeptide having the amino acid sequence of SEQ ID NO:2.

[0020] According to an aspect of some embodiments of the present invention, there is provided a method for preparing a modified uricase according to any of the embodiments described herein for the modified uricase, comprising the steps of: (a) contacting a polypeptide with a cross-linking agent comprising a poly(alkylene glycol) moiety and at least two aldehyde groups to obtain a conjugate of the polypeptide and the cross-linking agent; and (b) contacting the conjugate with a reducing agent.

[0021] According to an aspect of some embodiments of the present invention, there is provided a method for reducing the level of uric acid in a medium, the method comprising contacting the medium with a modified uricase according to any of the embodiments described herein with respect to the modified uricase.

[0022] In some embodiments of any of the present invention, the polypeptide is a recombinant polypeptide.

[0023] In some embodiments of any of the present invention, the polypeptide is a plant recombinant polypeptide.

[0024] In some embodiments of any of the present invention relating to modified uricase, the molecular weight of the bifunctional linking moiety ranges from about 1.5 kDa to about 4 kDa.

[0025] In some embodiments of any of the present invention relating to modified uricase, the molecular weight of the bifunctional linking moiety ranges from about 2 kDa to about 3.5 kDa.

[0026] In some embodiments of any of the inventions relating to modified uricase, the bifunctional linking moiety comprises an alkylene group covalently bonded to the nitrogen atom of an amine group in the uricase polypeptide.

[0027] In some of the embodiments of any of the present invention relating to an amine group in a polypeptide, the amine group is comprised in a lysine residue side chain.

[0028] In some of the embodiments of any of the inventions relating to modified uricase, the uricase polypeptide is conjugated to an average of at least eight bifunctional linking moieties.

[0029] In some of the embodiments of any of the invention relating to a plurality of polypeptides, each polypeptide is conjugated to an average of at least 8 bifunctional linking moieties.

[0030] In some embodiments of any of the present invention relating to modified uricase, at least 30% of the lysine residue side chains in the modified uricase are covalently attached to at least one bifunctional linking moiety.

[0031] In some embodiments of any of the present invention relating to modified uricase, the bifunctional linking moiety is represented by Formula I: -CH2-L1-[O-(CH2)m]nO-L2-CH2- Formula I (In the ceremony L1 and L2 are each independently a hydrocarbon moiety or absent; m is an integer ranging from 2 to 10; n is an integer ranging from 2 to 1000. It has.

[0032] In some embodiments of any of the present invention relating to Formula I, n ranges from 30-100.

[0033] In some embodiments of any of the present invention relating to Formula I, at least one or both of L1 and L2 is unsubstituted alkylene.

[0034] In some of the embodiments of any of the present invention relating to modified uricase, the poly(alkylene glycol) moiety is a polyethylene glycol moiety.

[0035] In some of the embodiments of any of the present invention relating to modified uricase, the modified uricase is in the form of a tetramer.

[0036] In some of the embodiments of any of the present invention relating to modified uricase, the modified uricase is in the form of a cross-linked tetramer.

[0037] In some embodiments of any of the present invention relating to a modified uricase, the modified uricase comprises at least one polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO:4, and homologs thereof.

[0038] In some embodiments of any of the present invention relating to a modified uricase, the modified uricase comprises at least one polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, and homologs thereof.

[0039] In some of the embodiments of any of the inventions relating to modified uricase, the modified uricase is characterized by a plasma half-life of at least 50 hours in rats.

[0040] In some of the embodiments of any of the present invention relating to modified uricase, the modified uricase is for use in treating a disease or disorder in which uricase activity is beneficial.

[0041] In some of the embodiments of any of the present invention relating to modified uricase, the modified uricase is for use in treating a disease or disorder associated with excessive uric acid levels.

[0042] In some of the embodiments of any of the inventions relating to a disease or disorder, the disease or disorder is selected from the group consisting of gout, diabetes, kidney stones, tumor lysis syndrome, hemorrhagic shock, malaria, allergic inflammation, renal dysfunction, viral infection, acute gastroenteritis, placentitis, sterile inflammation, pregnancy complications, multiple sclerosis, inflammatory bowel disease, gastrointestinal infection, and Lesch-Nyhan syndrome.

[0043] In some embodiments of any of the inventions relating to treatment, the treatment comprises administering the modified uricase at least every other week.

[0044] In some embodiments of any of the inventions relating to treatment, the treatment comprises administering the modified uricase at least every two months.

[0045] In some embodiments of any of the inventions relating to treatment, the treatment comprises administering modified uricase at a dosage of 8 mg / month or less.

[0046] In some embodiments of any of the methods of the present invention, the reducing agent is selected from the group consisting of picoline borane complex and cyanoborohydride.

[0047] In some embodiments of any of the methods of the present invention, the crosslinker is represented by Formula II: HC(=O)-L1-[O-(CH2)m]nO-L2-C(=O)H Formula II (In the ceremony L1 and L2 are each a hydrocarbon moiety; m is an integer ranging from 2 to 10; n is an integer ranging from 2 to 1000. It has.

[0048] In some embodiments of any of the methods of the present invention, the molecular weight of the cross-linking agent ranges from about 1.5 kDa to about 4 kDa.

[0049] In some embodiments of any of the methods of the invention, the method comprises contacting the polypeptide in tetrameric form with a cross-linking agent.

[0050] In some embodiments of any of the methods of the invention, the molar ratio of cross-linker to polypeptide ranges from 100:1 to 10,000:1.

[0051] In some embodiments of any of the methods of the invention, the medium is tissue of a subject in need of administration, and the method comprises administering modified uricase to the subject.

[0052] In some embodiments of any of the inventions directed to administration to a subject, the subject is suffering from a disease or disorder selected from the group consisting of gout, diabetes, kidney stones, tumor lysis syndrome, hemorrhagic shock, malaria, allergic inflammation, renal dysfunction, viral infection, acute gastroenteritis, placentitis, sterile inflammation, pregnancy complications, multiple sclerosis, inflammatory bowel disease, gastrointestinal infection, and Lesch-Nyhan syndrome.

[0053] In some embodiments of any of the inventions relating to administration to a subject, administration occurs at least every other week.

[0054] In some embodiments of any of the inventions relating to administration to a subject, administration occurs at least every two months.

[0055] In some embodiments of any of the inventions relating to administration to a subject, the dosage of uricase administered to the subject is 8 mg / month or less.

[0056] Unless otherwise defined, all technical and / or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the present invention, exemplary methods and / or materials are described below. In case of conflict, the present patent specification, including definitions, will control. Furthermore, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.

[0057] Certain embodiments of the present invention are described herein, by way of example only, with reference to the accompanying drawings. While particular reference will now be made in detail to the drawings, it is emphasized that the details shown are for purposes of illustration and are illustrative descriptions of embodiments of the invention. In this regard, the description provided with the drawings will make apparent to those skilled in the art how embodiments of the invention may be practiced. [Brief explanation of the drawings]

[0058] [Figure 1] FIG. 1 shows a diagram illustrating modified uricase according to some embodiments of the present invention, as well as a method for preparing modified uricase according to some embodiments of the present invention by contacting uricase with an aldehyde-containing cross-linker and a reducing agent. [Figure 2] Figure 2 shows gel images of SDS-PAGE analysis (under denaturing conditions) of plant recombinant wild-type Candida uricase (prU-C) and the C250K mutant (prU-C250K) before (-) and after (+) freeze / thaw (Fr / Th) cycles at a concentration of 0.3 mg / mL (measured by optical density) in 25 mM Tris (pH 8.4). (Estimated molecular weights are shown in the center.) High molecular weight structures associated with uricase (structures formed from multiple subunits, such as dimers and tetramers) are indicated by curly brackets on the left. [Figure 3]FIG. 3 is a graph showing the enzymatic activity (normalized to the activity at t=0) of uricase variants (prU-A, prU-C, prU-C250K, and prU-G) as a function of incubation time in human plasma (2 μg / mL uricase at 37° C.), normalized to the activity at t=0. [Figure 4] Figure 4 shows a gel image of SDS-PAGE analysis of unmodified prU-C and prU-C cross-linked with PEG bisaldehyde (bisPEG ALD) having PEG of 1000 Da, 2000 Da, 5000 Da, or 10,000 Da (molecular weight markers are shown on the right). [Figure 5] Figure 5 shows a gel image of SDS-PAGE analysis of unmodified prU-A (lane labeled "-") and prU-A cross-linked with PEG bisaldehyde (bis-Ald-PEG) having PEG of 600 Da, 1000 Da, 2000 Da, 3400 Da, 5000 Da, or 10000 Da (molecular weight markers are shown on the right). [Figure 6] Figure 6 shows a gel image of SDS-PAGE analysis of unmodified prU-G and prU-G cross-linked with 200 or 1000 equivalents of bis-Ald-PEG with PEG of 2000 Da, 3400 Da, or 5000 Da (molecular weight markers are shown on the left). [Figure 7] Figure 7 shows a gel image of SDS-PAGE analysis of unmodified prU-A and prU-A cross-linked with 2000 Da bifunctional PEG1000 equivalents bearing aldehyde (ALD) or N-hydroxysuccinimide (NHS) functional groups (molecular weight markers are shown on the left). [Figure 8]Figures 8A and 8B show diagrams and bar graphs. Figure 8A is a diagram of immunization of rats with prU-A crosslinked with 2000 Da bis-AldPEG or 2000 Da bis-NHSPEG and alum adjuvant (the upper arrow indicates the day of immunization, and the lower arrow indicates the day of serum collection). Figure 8B is a bar graph showing antibody titers against test proteins in rats immunized with prU-A crosslinked with bis-Ald-PEG (rats 7-12) or bis-NHS-PEG (rats 13-18) according to the timeline in Figure 8A. Three bars for each rat show antibody titers on days 30 (left bar), 50 (middle bar), and 72 (right bar). [Figure 9] Figures 9A and 9B show graphs showing the percentage inhibition of binding of antibodies against prU-A cross-linked with bis-Ald-PEG (Figure 9A) or bis-NHS-PEG (Figure 9B) to such cross-linked prU-A compared with inhibition by unmodified prU-A by competitive ELISA. Serum samples from rats immunized with test substances were preincubated with increasing concentrations of modified or unmodified prU-A ("inhibitor" on the x-axis). The percentage of binding after inhibition by preincubation with either modified or unmodified prU-A is shown as a function of the concentration of protein (inhibitor) used in the preincubation. [Figure 10] Figure 10 is a bar graph showing antibody titers (against the modified prU tested) in individual rats immunized with prU-A cross-linked with PEG bis-aldehyde having a 2000 Da PEG (rats 1-5) or prU-A cross-linked with PEG bis-aldehyde having a 3400 Da PEG (rats 11-15), or with prU-C cross-linked with PEG bis-aldehyde having a 2000 Da PEG (rats 21-25) or prU-C cross-linked with PEG bis-aldehyde having a 3400 Da PEG (rats 26-30) and alum adjuvant. Blood samples were collected on days 30 (bleed 1), 51 (bleed 2), and 72 (bleed 3), and immunizations were performed on days 1, 21, 42, and 63. [Figure 11]Figure 11 is a table showing the recognition of unmodified prU-C250K, prU-C250K modified with monofunctional 10 kDa PEG, and prU-C250K modified with bifunctional 3400 Da PEG by pre-existing antibodies from healthy human donors using ELISA. Values ​​represent the OD ratio between the ELISA results of the sample and negative control, highlighting only the results of donors showing a positive response with an OD ratio of at least 2 (34 of 102 donors, each represented by a row). [Figure 12] Figure 12 is a graph showing the stability of two batches (346 and 347) of prU-C250K cross-linked with bis-Ald-PEG3400Da in human plasma at 37°C, as assessed by enzyme activity (normalized to activity at t=0). [Figure 13] Figures 13A and 13B are diagrams and bar graphs. Figure 13A is a diagram showing a pharmacokinetic (PK) and immunogenicity study comparing unmodified prU-C250K with crosslinked prU-C250K-bis-Ald-PEG3400Da in female rats. The study included six intravenous (IV) administrations (upper arrows) followed by PK and antibody titer assessments (lower arrows indicate bleed dates for analysis, thick arrows indicate antibody assessment dates, and thin arrows indicate PK time points). Figure 13B is a bar graph showing anti-prU-C250K antibody titers on days 0 (Pre1), 14 (bleed 1), 31 (bleed 2), 44 (bleed 3), 59 (bleed 4), and 73 (bleed 5) in six rats immunized with unmodified prU-C250K. [Figure 14-1]Figures 14A, 14B, 14C, and 14D are graphs showing the pharmacokinetic profile of prU-C250K-bis-Ald-PEG3400. The natural logarithm (LN) of plasma protein concentration over time is shown in naive rats (Figures 14A and 14B) or rats dosed six times (Figures 14C and 14D), along with a linear fit to the data (dashed line and equation and R2 values). Total prU-C250K-bis-Ald-PEG3400 concentrations were measured by a complementary ELISA assay (Figures 14A and 14C). Active protein concentrations were assessed by measuring uricase activity (Figures 14B and 14D). The calculated half-lives and areas under the curve (AUC) were 54.0 hours and 61.07 mg*min / mL (Figure 14A), 64.8 hours and 65.95 mg*min / mL (Figure 14B), 70.5 hours and 80.4 mg*min / mL (Figure 14C), and 68.4 hours and 58.5 mg*min / mL (Figure 14D). [Figure 14-2] Same as above [Figure 15] 15 is a Michaelis-Menten plot showing the reaction rate of exemplary cross-linked uricase (squares) and pegloticase (circles) as a function of substrate (UA) concentration. Reaction rates were measured by incubation at 37°C for 5 minutes and assessing the linear increase in fluorescence of the oxidized Ampliflu™ probe with the production of HO (each data point represents the average of triplicate experiments). [Figure 16] FIG. 16 is a graph showing plasma concentrations of exemplary cross-linked uricase and pegloticase in rats as a function of time after the first injection of enzyme. [Figure 17] FIG. 17 is a graph showing plasma concentrations of exemplary cross-linked uricase and pegloticase in rats as a function of time after the fourth injection of enzyme. [Figure 18] FIG. 18 is a bar graph showing the plasma half-life of exemplary cross-linked uricase and pegloticase in rats after the first (naive) and fourth (repeat) injections (based on the data shown in FIGS. 16 and 17). DETAILED DESCRIPTION OF THE INVENTION

[0059] The present invention, in some embodiments thereof, relates to therapy, and more particularly, but not exclusively, to novel forms of uricase and their uses, such as in lowering uric acid levels.

[0060] Before describing at least one embodiment of the present invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details set forth in the following detailed description or illustrated by the examples, as the invention is capable of other embodiments or of being practiced or carried out in various ways.

[0061] As discussed herein above, uricase is a foreign protein to humans and is therefore highly immunogenic, which poses a significant obstacle to its therapeutic use. In addition, uricase is generally administered by injection or infusion, which can be very inconvenient and can be unstable during handling or storage.

[0062] In the search for improved uricase, the present inventors have successfully designed and implemented modified uricases that exhibit reduced or nearly abolished immunogenicity and good stability during storage and in vivo. The present inventors have shown that the properties of such crosslinked uricases are desirable compared to those of PEGylated uricases known in the art (e.g., in terms of low immunogenicity and enhanced half-life in vivo).

[0063] During the course of reducing the present invention to practice, the inventors have discovered variant uricase polypeptides that are associated with improved performance, including reduced immunogenicity and reduced aggregation.

[0064] Reference is now made to the various figures: Figure 2 shows that an exemplary uricase variant (SEQ ID NO: 2) is associated with reduced aggregation of uricase.

[0065] Figure 3 shows exemplary uricase variants that exhibit stability in human plasma. Figure 12 shows that crosslinked uricase according to exemplary embodiments exhibits high stability in human plasma. Figures 14A-14D show that the in vivo half-life in rats of crosslinked uricase according to exemplary embodiments exceeds 50 hours, even after repeated administration.

[0066] Figures 4, 5 and 6 show that the cross-linking efficiency of various uricase variants with polyethylene glycol linking moieties is greatest when the linking moieties have a molecular weight greater than 1000 Da and less than 5000 Da.

[0067] FIG. 7 shows that both the bis-NHS and bis-aldehyde crosslinkers efficiently crosslinked uricase, and that crosslinking with the bis-aldehyde agent resulted in more efficient modification than the bis-N-hydroxysuccinimide agent.

[0068] 8A-8B show that cross-linking using a bis-aldehyde agent significantly reduces the in vivo immunogenicity of cross-linked uricase compared to cross-linking using a bis-N-hydroxysuccinimide cross-linker.

[0069] Figure 10 shows that cross-linking of various uricase variants can result in low levels of immunogenicity in vivo. In contrast, Figures 13A-B show that unmodified uricase is significantly immunogenic.

[0070] Figure 11 shows that upon crosslinking with an exemplary (short) PEG linking moiety, antigenicity (as represented by the amount of pre-existing antibodies in healthy human donors) is lower compared to modification with 10 kDa PEG (the modification used in pegloticase).

[0071] FIG. 15 shows that exemplary cross-linked uricases have significantly stronger uricase activity than pegloticase in vitro.

[0072] Figures 16-18 show that exemplary cross-linked uricases have longer plasma half-lives than pegloticase in vivo.

[0073] Modified uricase: According to one aspect of some embodiments of the present invention, there is provided a modified uricase comprising at least one uricase polypeptide (as that term is defined herein), wherein the at least one uricase polypeptide is crosslinked by at least one linking moiety comprising a poly(alkylene glycol) moiety, preferably by at least one bifunctional linking moiety comprising a poly(alkylene glycol) moiety.

[0074] As used herein, the term "modified uricase" refers to any structure comprising at least one uricase polypeptide (as that term is defined herein) to which one or more additional moieties (other than uricase) are covalently attached, and is not meant to be limited beyond those expressly set forth herein.

[0075] As used herein, the terms "crosslink," "crosslinked," and any variations thereof, refer to individual moieties that are covalently attached to another molecule (e.g., covalently attached to two or more different atoms) at each of two or more different sites on the molecule. The crosslinks can be intramolecular, i.e., the individual moieties are covalently attached to two or more different sites on a single molecule, such as a single polypeptide (e.g., the conjugate: [ka] where moiety B is covalently attached to moiety A at two different sites, as in the conjugate ABA), or intermolecular, i.e., where each of the aforementioned moieties is covalently attached to each of two or more different molecules, e.g., two or more polypeptides (e.g., where moiety B is covalently attached to two different A moieties, as in the conjugate ABA), or there may be a combination of intramolecular and intermolecular crosslinks (e.g., as in the conjugate [ka] As in, two B moieties participate in intramolecular crosslinking and one in intermolecular crosslinking).

[0076] Typically, but not necessarily, the individual moieties described above are described herein as "bridges" and one or more other molecules are described as being "bridged" (e.g., in the conjugate ABA, moiety B is typically described as "bridges" two A moieties, and the two A moieties are "bridged" by moiety B).

[0077] As used herein, the term "linking moiety" refers to any moiety (component of a molecule) that is covalently attached to another moiety and / or molecule at two or more distinct sites; i.e., a moiety that crosslinks one or more other molecules (e.g., one or more polypeptides) as defined herein. A "bifunctional linking moiety" refers to a linking moiety that is covalently attached to two (but not more) distinct sites.

[0078] It is understood that the bridging and linking moieties described herein are distinct from various polypeptide modifications known in the art that involve the attachment of a moiety to a single site on a polypeptide. For example, PEGylation typically involves the attachment of polyethylene glycol (PEG) to a single site. As shown in the Examples section herein, uricase modified with a linking moiety can exhibit significantly different properties than corresponding uricase modified with a chemically similar moiety that is monofunctional, such as that typically PEGylated (as found in pegloticase).

[0079] Without being bound by any particular theory, it is believed that linking moieties are more sterically confined than monofunctional moieties, which may increase the total number of sites attached to such moieties and / or provide more efficient masking of the polypeptide from its surroundings (e.g., for a given number and / or mass of modifying moieties).

[0080] As used herein, the term "uricase" encompasses any enzyme classified in EC 1.7.3.3 (which catalyzes the oxidation of urate to 5-hydroxyurate, involving the conversion of O to HO) or any enzyme classified in EC 1.14.13.113 (which catalyzes the oxidation of urate to 5-hydroxyurate, involving the oxidation of FADH and the conversion of O to HO), and includes both proteins having the amino acid sequence of the naturally occurring enzyme and proteins having homologous amino acid sequences (e.g., as that term is defined herein, in accordance with any of the embodiments described herein with reference to homologs).

[0081] In some optional embodiments described herein, the uricase is an EC 1.7.3.3 uricase.

[0082] As used herein, the term "uricase polypeptide" refers to a separate polypeptide chain contained in a uricase. For example, a tetrameric uricase may contain four uricase polypeptides, or a uricase may contain only one uricase polypeptide (e.g., consisting of a uricase polypeptide). The uricase polypeptide is optionally substituted with one or more substituents (e.g., other than a linking moiety described herein), such as a sugar moiety and / or a lipid moiety, and / or any other substituent known in the art for attachment to naturally occurring polypeptides.

[0083] In some optional embodiments described herein, the modified uricase is in the form of a multimeric structure. That is, the modified uricase comprises multiple uricase polypeptide chains. Such multimeric forms may be, for example, dimers, trimers, tetramers, hexamers, octamers, or larger multimeric forms. In some such embodiments, the multimeric forms are similar in structure (e.g., the number and / or orientation of uricase polypeptide chains) to the unmodified form of uricase, such as the tetramer of many uricase variants.

[0084] At least some of the uricase polypeptides in the multimeric structure may optionally be covalently linked to one another, e.g., by intermolecular crosslinks via linking moieties described herein. Alternatively or additionally, at least some of the uricase polypeptides in the multimeric structure may optionally be associated with other polypeptides in the multimeric structure only by non-covalent interactions (e.g., all crosslinks via linking moieties described herein are intramolecular crosslinks).

[0085] As will be apparent to those of skill in the art, the modified uricases described herein have a complex polymeric nature (e.g., due to the presence of one or more polypeptide and / or one or more polymeric linking moieties) and therefore are typically produced in the form of a collection of similar but somewhat distinct molecules and / or multimeric structures. For example, the number of linking moieties and / or the position at which one or more linking moieties are attached to the uricase polypeptide can vary.

[0086] In some of any respective embodiments, a uricase polypeptide (e.g., each of the multiple uricase polypeptides in a multimeric structure described herein) is linked to an average of at least two linking moieties (according to any of the respective embodiments described herein), optionally at least three, at least four, at least five, at least six, at least seven, at least eight, at least ten, at least twelve, at least fourteen, or even at least sixteen linking moieties. The linking moieties are optionally bifunctional linking moieties. In some such embodiments, each of the linking moieties is linked to two lysine residues.

[0087] In some embodiments, at least 10% of the lysine residue side chains in the modified uricase are attached to a linking moiety (e.g., according to any of the embodiments described herein relating to linking moieties attached to lysine residue side chains), and optionally at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or even at least 90% of the lysine residue side chains are attached to a linking moiety. Optionally, the linking moiety is a bifunctional linking moiety. In some embodiments, substantially all of the lysine residue side chains are attached to a linking moiety.

[0088] Determining the average number of linking moieties attached to each polypeptide or the average number of lysine residue side chains attached to linking moieties determines the average value for a population of modified uricase molecules and / or multimeric structures (e.g., a population as discussed hereinabove). For example, each linking moiety attached to two polypeptides corresponds to 0.5 linking moieties per polypeptide.

[0089] In addition to the linking moieties described herein, the modified uricase may optionally be further modified with one or more additional moieties, e.g., one or more moieties having a structure similar to the linking moieties described herein (e.g., comprising a poly(alkylene glycol) moiety described herein and / or attached to a polypeptide lysine residue in the manner described herein for the linking moiety), but attached to the uricase polypeptide at only one site. Such (monofunctional) moieties may be produced, for example, by incomplete cross-linking reactions in which any attachment sites (e.g., lysine residues) present on the polypeptide are attached to other sites and / or sterically blocked.

[0090] Furthermore, in any of the embodiments herein directed to a bifunctional linking moiety, the modified uricase may optionally be further modified with one or more linking moieties that are not bifunctional, e.g., linking moieties (optionally branched linking moieties) attached to three, four, or more polypeptide moieties. In some such embodiments, the bifunctional moiety may be generated, for example, by an incomplete cross-linking reaction of a compound containing three or more functional groups capable of binding to a polypeptide, e.g., a potential binding site (e.g., a lysine residue) on the polypeptide is bound to and / or sterically blocked by multiple moieties, thereby preventing binding at a third site.

[0091] In some optional embodiments described herein, the modified uricase is characterized by a longer in vivo half-life than a comparable unmodified uricase (i.e., not comprising a linking moiety as described herein). In some such embodiments described herein, the half-life of the modified uricase is at least 20% longer than the half-life of the comparable unmodified uricase. In some embodiments, the half-life of the modified uricase is at least 50% longer than the half-life of the comparable unmodified uricase. In some embodiments, the half-life of the modified uricase is at least 100% longer, i.e., at least two-fold longer, than the half-life of the comparable unmodified uricase. In some embodiments, the half-life of the modified uricase is at least three times longer than the half-life of the comparable unmodified uricase. In some embodiments, the half-life of the modified uricase is at least five times longer than the half-life of the comparable unmodified uricase. In some embodiments, the half-life of the modified uricase is at least 10 times the half-life of the comparable unmodified uricase. In some embodiments, the half-life of the modified uricase is at least 20 times the half-life of the comparable unmodified uricase. In some embodiments, the half-life of the modified uricase is at least 50 times the half-life of the comparable unmodified uricase. In some embodiments, the half-life of the modified uricase is at least 100 times the half-life of the comparable unmodified uricase.

[0092] The half-life of a (modified and / or unmodified) uricase may be determined, for example, by measuring the amount of the test uricase in the blood (e.g., in plasma) over time after injection of the test uricase into a subject (e.g., in a human and / or rat). As exemplified herein, the amount of uricase may be measured using antibodies to the test uricase (e.g., by ELISA) and / or by measuring the amount of enzymatic activity characteristic of the uricase.

[0093] In some optional embodiments described herein, the modified uricase is characterized by a plasma half-life in rats (e.g., as measured by antibody recognition and / or enzymatic activity) of at least 40 hours. In some such embodiments, the half-life is at least 50 hours. In some such embodiments, the half-life is at least 60 hours. In some such embodiments, the half-life is at least 70 hours. In some such embodiments, the half-life is at least 80 hours. In some such embodiments, the half-life is at least 100 hours. In some embodiments, the half-life is at least 1 week, or at least 2 weeks, or at least 3 weeks, or at least 4 weeks.

[0094] The longer half-life of the modified uricase according to any of the embodiments described herein may optionally be related to the larger molecular weight of the modified uricase (which may decrease the rate at which it is removed from the bloodstream, e.g., by filtration in the kidneys) and / or the lower immunogenicity of the modified uricase (which may decrease the rate at which it is inactivated and / or destroyed by the immune system).

[0095] Connecting part: A linking moiety according to any of the embodiments described herein may be optionally attached to a uricase polypeptide according to any of the embodiments described herein (e.g., in the respective sections herein) in any manner described herein (e.g., according to any of the embodiments described herein with respect to the nature of the crosslinks and / or the overall structure of the modified uricase).

[0096] As discussed herein, the linking moiety comprises a poly(alkylene glycol) moiety.

[0097] The phrase "poly(alkylene glycol)" as used herein encompasses a group of polyether polymers sharing the following general formula: -[O-(CH)]O-, where m represents the number of methylene groups present in each alkylene glycol unit and n represents the number of repeating units, and thus the size or length of the polymer. For example, when m=2, the polymer is called polyethylene glycol, and when m=3, the polymer is called polypropylene glycol.

[0098] In some embodiments, m is an integer greater than 1 (eg, m=2, 3, 4, etc.).

[0099] Optionally, m may vary between units in the poly(alkylene glycol) chain, for example, a poly(alkylene glycol) chain may include both ethylene glycol (m=2) and propylene glycol (m=3) units linked together.

[0100] The phrase "poly(alkylene glycol)" also encompasses analogs thereof in which the oxygen atom is replaced with another heteroatom, such as, for example, S and -NH-. The term further encompasses derivatives of the above in which one or more of the methylene groups comprising the polymer are substituted. Examples of optional substituents on the methylene group include, but are not limited to, alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy, hydroxy, oxo, thiol, and thioalkoxy. In some embodiments, the substituents on the methylene group, if present, are alkyl, optionally C 1-4 -alkyl, and optionally methyl.

[0101] As used herein, the phrase "alkylene glycol unit" encompasses the -O-(CH)- group or analog thereof described hereinabove, which forms the backbone of a poly(alkylene glycol), wherein the (CH) (or analog) is bonded to an oxygen atom (or a heteroatom analog thereof) at the terminal end of the poly(alkylene glycol) (represented by the formula -[O-(CH)]O-) or heteroatom analog thereof, or at the terminal end of a heteroatom belonging to another alkylene glycol unit or a uricase polypeptide (in the case of a terminal unit), and the O (or said terminal oxygen atom) or heteroatom analog thereof is bonded to the (CH) (or analog thereof) of another alkylene glycol unit or to a functional group (according to any of the embodiments described herein) that forms a bond with a uricase polypeptide.

[0102] The alkylene glycol unit may be branched so as to be linked to three or more adjacent alkylene glycol units, each of which is part of a poly(alkylene glycol) chain. Such a branched alkylene glycol unit is bonded to one adjacent alkylene glycol unit through its heteroatom, and the heteroatoms of the remaining adjacent alkylene glycol units are each bonded to a carbon atom of the branched alkylene glycol unit. Furthermore, a heteroatom (e.g., nitrogen) may be bonded to two or more carbon atoms of the alkylene glycol unit of which it is a part to form a branched alkylene glycol unit (e.g., [(-CH)]N-, etc.).

[0103] In exemplary embodiments, at least 50% of the alkylene glycol units are identical, e.g., they contain the same heteroatom and the same m value as each other. Optionally, at least 70%, optionally at least 90%, and optionally 100% of the alkylene glycol units are identical. In exemplary embodiments, the heteroatoms attached to the identical alkylene glycol units are oxygen atoms, and / or the alkylene glycol units are unsubstituted. In further exemplary embodiments, m is 2 for the identical units.

[0104] In one embodiment, the poly(alkylene glycol) is a single linear chain (preferably polyethylene glycol (PEG)), and the two ends of the chain are each independently attached directly or indirectly (e.g., via a functional group described herein) to the uricase polypeptide.

[0105] As used herein, the term "polyethylene glycol" refers to a poly(alkylene glycol), as defined herein above, in which at least 50%, at least 70%, at least 90%, and preferably 100% of the alkylene glycol units are -CHCH-O-. Similarly, the phrase "ethylene glycol unit" is defined herein as a -CHCHO- unit.

[0106] According to an optional embodiment, the linking moiety comprises polyethylene glycol or an analog thereof, which may be represented by the general formula: -(Y1-CR1R2-CR3R4)n-Y2- wherein Y1 and Y2 are each independently O, S, or NR5 (optionally O); n is optionally an integer from 2 to 1000 (optionally 10 to 300, optionally 30 to 100), although higher values ​​of n are contemplated; Each of R1, R2, R3, R4, and R5 is independently hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy, hydroxy, oxo, thiol, and / or thioalkoxy.

[0107] In some of any of the respective embodiments, R1, R2, R3, R4, and R5 are each independently hydrogen or alkyl, and optionally hydrogen or C 1-4- alkyl, and optionally hydrogen or methyl. In an exemplary embodiment, R1, R2, R3, R4, and R5 are each hydrogen.

[0108] The polyethylene glycol or analogue thereof may optionally comprise a copolymer, eg, the Y1-CR1R2-CR3R4 units in the above formula are not all identical to one another.

[0109] In some embodiments, at least 50% of the Y1-CR1R2-CR3R4 units are identical. Optionally, at least 70%, optionally at least 90%, and optionally 100% of the Y1-CR1R2-CR3R4 units are identical.

[0110] Optionally, the linking moiety is branched, e.g., for one or more Y1-CR1R2-CR3R4 units in the above formula, at least one of R1, R2, R3, R4, and R5 is -(Y1-CR1R2-CR3R4)p-Y2-, where R1 through R5 and Y1 and Y2 are as defined herein, and p is an integer as defined herein for n (e.g., 2 to 1000) according to any of the embodiments.

[0111] The linking moiety optionally comprises at least two functional groups, each of which forms a covalent bond with the uricase polypeptide. Exemplary functional groups include an alkylene group and a carbonyl (—C(═O)—). The alkylene or carbonyl may optionally be attached to a nitrogen atom (e.g., an amine group) of the polypeptide, for example, so that they together form an amine group or an amide group, respectively. The functional groups may optionally be terminal groups of the linking moiety, with the entire length of the poly(alkylene glycol) being between the two functional groups. Each functional group may optionally be directly attached to the poly(alkylene glycol) moiety (according to any of the embodiments described herein) or indirectly attached via a linking group (as that term is defined herein), which is optionally a hydrocarbon moiety.

[0112] In any of several embodiments described herein, the linking moiety (optionally, the bifunctional linking moiety) comprises an alkylene group (e.g., an unsubstituted alkylene group) covalently bonded to a nitrogen atom of an amine group in the polypeptide, e.g., an amine group at a lysine residue side chain and / or the N-terminus.

[0113] As exemplified herein, such alkylene groups covalently bonded to a nitrogen atom can be obtained by reacting an aldehyde group with an amine group (e.g., by methods described herein), optionally in the presence of a reducing agent.

[0114] Without being bound to any particular theory, cross-linking via alkylene groups covalently bonded to polypeptide nitrogen atoms is believed to be advantageously less immunogenic than alternative cross-linking techniques, such as forming an amide bond between a carbonyl (-C(=O)-) group (optionally derived by condensation of a carboxylate group) and a polypeptide amine group.

[0115] FIG. 1 schematically illustrates a modified uricase (e.g., in the form of a tetramer) according to some embodiments of the present invention, in which some PEG moieties are attached to multiple amine groups on a polypeptide (e.g., by reductive amination according to any of the embodiments described herein), some PEG moieties are attached to a single amine group on a polypeptide, and unreacted functional groups (e.g., aldehydes) remain (optionally generated by an incomplete crosslinking reaction according to any of the embodiments described herein). Additionally, there may be remaining amine groups not attached to any moiety (i.e., -NH groups). As shown herein, the modified uricase may optionally be generated by reacting uricase (e.g., a uricase tetramer) with a bis-aldehyde reagent in the presence of a reducing agent.

[0116] In the case of uricase comprising multiple polypeptide units (e.g., a uricase tetramer), PEG moieties may optionally (but not necessarily) be attached to the polypeptides so as to crosslink (directly and / or indirectly through one or more intervening polypeptides) some or all of the polypeptides (e.g., all four polypeptides of a tetramer) to one another. Optionally, the crosslinks are such that the polypeptides do not dissociate under denaturing conditions.

[0117] Modified uricases that differ from the illustration in FIG. 1 by having a different quaternary structure (e.g., a structure other than a tetramer), being formed by a different reaction (e.g., other than reaction with a bisaldehyde agent in the presence of a reducing agent), containing different functional groups (e.g., other than an aldehyde), containing different groups for attaching the polypeptide to the linking moiety (e.g., other than an -NH- group), and / or containing different linking moieties (e.g., containing polymers other than PEG) are also contemplated.

[0118] In any of several embodiments described herein, the bifunctional linking moiety is represented by Formula I: -CH2-L1-[O-(CH2)m]nO-L2-CH2- Formula I (In the ceremony L1 and L2 are each a linking moiety (as defined herein) or absent (optionally the same or different linking moieties may be hydrocarbon moieties), preferably a linking moiety is a hydrocarbon moiety; m is an integer ranging from 2 to 10; n is an integer ranging from 2 to 1000.

[0119] In some optional embodiments herein directed to formulas including the variable m, m is 2, 3, or 4. In some embodiments, m is 2 or 3. In some embodiments, m is 2, such that the linking moiety includes a polyethylene glycol moiety (having n ethylene glycol subunits).

[0120] In some optional embodiments herein relating to formulas including the variable n, n is at least 10 (e.g., 10 to 300, or 10 to 100). In some such embodiments, n is at least 30 (e.g., 30 to 300, or 30 to 100, or 30 to 80, or 30 to 60). In some embodiments, n is at least 40 (e.g., 40 to 300, or 40 to 100, or 40 to 80, or 40 to 60). In some embodiments, n is at least 50 (e.g., 50 to 300, or 50 to 100, or 50 to 80, or 50 to 60). In some embodiments, n is at least 60 (e.g., 60 to 300, or 60 to 100, or 60 to 80). In some embodiments, n is at least 60 (e.g., 60 to 300, or 60 to 100, or 60 to 80). In some embodiments, n is at least 70 (eg, 70 to 300, or 70 to 100, or 70 to 80).

[0121] In some optional embodiments herein relating to formulas including variables m and n, n is at least 10 (e.g., 10 to 300, or 10 to 100), and m is 2, 3, or 4, preferably 2 or 3, and more preferably 2. In some such embodiments, n is at least 30 (e.g., 30 to 300, or 30 to 100, or 30 to 80, or 30 to 60). In some embodiments, n is at least 40 (e.g., 40 to 300, or 40 to 100, or 40 to 80, or 40 to 60). In some embodiments, n is at least 50 (e.g., 50 to 300, or 50 to 100, or 50 to 80, or 50 to 60). In some embodiments, n is at least 60 (e.g., 60 to 300, or 60 to 100, or 60 to 80). In some embodiments, n is at least 60 (e.g., 60 to 300, or 60 to 100, or 60 to 80). In some embodiments, n is at least 70 (e.g., 70 to 300, or 70 to 100, or 70 to 80).

[0122] In some optional embodiments described herein, L and L are each independently substituted or unsubstituted alkylene, optionally having 1 to 4 carbon atoms, 1 to 3 carbon atoms, and 1 or 2 carbon atoms. In some such embodiments, the alkylene is unsubstituted, e.g., CH or CHCH.

[0123] The linking moiety of Formula I (according to any of the embodiments) may optionally be attached at one or both termini to a nitrogen atom of the polypeptide. In such embodiments, the terminal -CH- (optionally in combination with at least a portion of L and / or L) forms an alkylene (optionally unsubstituted alkylene) attached to a nitrogen atom of the polypeptide (according to any of the embodiments described herein).

[0124] In any of several embodiments described herein, the molecular weight of the linking moiety (optionally, the bifunctional linking moiety) is at least about 1.5 kDa. In some such embodiments, the molecular weight of the linking moiety is in the range of about 1.5 kDa to about 4 kDa. In some embodiments, the molecular weight of the linking moiety is in the range of about 1.5 kDa to about 3.5 kDa. In some embodiments, the molecular weight of the linking moiety is in the range of about 1.5 kDa to about 3 kDa. In some embodiments, the molecular weight of the linking moiety is in the range of about 1.5 kDa to about 2.5 kDa. In some exemplary embodiments, the molecular weight of the linking moiety is about 2 kDa.

[0125] In any of several embodiments described herein, the molecular weight of the linking moiety (optionally the bifunctional linking moiety) is at least about 2 kDa. In some such embodiments, the molecular weight of the linking moiety is in the range of about 2 kDa to about 4 kDa. In some embodiments, the molecular weight of the linking moiety is in the range of about 2 kDa to about 3.5 kDa. In some embodiments, the molecular weight of the linking moiety is in the range of about 2 kDa to about 3 kDa. In some embodiments, the molecular weight of the linking moiety is in the range of about 2 kDa to about 2.5 kDa.

[0126] In any of several embodiments described herein, the molecular weight of the linking moiety (optionally the bifunctional linking moiety) is at least about 2.5 kDa. In some such embodiments, the molecular weight of the linking moiety ranges from about 2.5 kDa to about 4 kDa. In some embodiments, the molecular weight of the linking moiety ranges from about 2.5 kDa to about 3.5 kDa.

[0127] In any of several embodiments described herein, the molecular weight of the linking moiety (optionally the bifunctional linking moiety) is at least about 3 kDa. In some such embodiments, the molecular weight of the linking moiety ranges from about 3 kDa to about 4 kDa. In some embodiments, the molecular weight of the linking moiety ranges from about 3 kDa to about 3.5 kDa. In some exemplary embodiments, the molecular weight of the linking moiety is about 3.4 kDa.

[0128] In some of any of the embodiments described herein, the molecular weight of the linking moiety (optionally the bifunctional linking moiety) is about 4 kDa or less. In some such embodiments, the molecular weight of the linking moiety is about 3.5 kDa or less. In some embodiments, the molecular weight of the linking moiety is about 3 kDa or less. In some embodiments, the molecular weight of the linking moiety is about 2.5 kDa or less.

[0129] As exemplified herein, linking moieties of the sizes described herein (e.g., at least about 1.5 kDa and / or up to about 4 kDa, and / or values ​​of the variables m and / or n described herein) may be associated with an advantageous combination of cross-linking efficiency and reduced immunogenicity compared to smaller and / or larger linking moieties.

[0130] Without being bound by any particular theory, it is believed that excessively small linking moieties may result in ineffective masking of the polypeptide (which is related to higher immunogenicity), for example, due to a smaller mass per linking moiety and / or due to a smaller amount of linking moiety attached to each polypeptide (e.g., the linking moiety is not long enough to efficiently bind to two separate binding sites, such as a pair of lysine residues). Furthermore, it is believed that excessively large linking moieties may result in ineffective masking of the polypeptide, for example, the attachment of a large linking moiety sterically hinders the attachment of additional linking moieties, leaving gaps in the masking of the polypeptide (e.g., where antibodies can enter).

[0131] Polypeptides: A uricase polypeptide moiety according to any of the embodiments described herein may optionally be combined with a linking moiety according to any of the embodiments described herein (e.g., in the respective sections herein) in any manner described herein (e.g., according to any of the embodiments described herein with respect to the nature of the crosslinks and / or the overall structure of the modified uricase).

[0132] The uricase polypeptides used in any of the embodiments described herein can be associated with any one or more uricases (as defined herein) known in the art. Modified uricases comprising multiple cross-linked uricase polypeptides (according to any of the embodiments described herein) can optionally comprise uricase polypeptides associated with a single uricase variant or different uricase variants.

[0133] It is expected that many related variants of uricase will be characterized (e.g., naturally occurring uricase variants) and / or developed (e.g., non-naturally occurring uricase variants) during the life of this application and any eventual patent, and the scope of the terms "uricase" and "uricase polypeptide" is intended to include a priori all such new variants and technologies.

[0134] Examples of uricase polypeptides that may be used in any of the embodiments described herein include, but are not limited to, uricase polypeptides from: ancient humans, pigs, baboons, Agrobacterium tumefaciens, Alicyclobacillus mali, Arthrobacter gangotriensis, Arthrobacter globiformis, Aspergillus flavus, Aspergillus udagawae, Aureobasidium pullulans EXF-150, Bacillus fastidiosus, Bacillus halodurans C-125, Bacillus subtilis str. 168, Bacillus sp. FJAT-21352, Bacillus sp. TB-90, Bacillus beveridgei, Bactrocera latifrons (fruit fly), Blastomyces dermatitidis, Camelus ferus (wild Bactrian camel), and Candida utillis, Candidatus Solibacter usitatus, Chlamydomonas reinhardtii, Cicer arietinum (chickpea), Deinococcus radiodurans, Deinococcus geothermalis, Drechmeria coniospora, Erinaceus europaeus (common hedgehog), Escherichia coli ISC56, Galdieria sulphuraria, Glycine max (soybean), Granulicella tundricola, Kyrpidia tusciae DSM 2912, Magnaporthiopsis poae, Microbacterium sp.zzj4-1, Neonectria ditissima, Nicotiana tabacum (tobacco), Paenibacillus darwinianus, Paenibacillus odorifer, Phaseolus vulgaris (kidney bean), Phialocephala scopiformis, Pseudomonas aeruginosa, Pygoscelis adeliae (Adelie penguin), Rousettus aegyptiacus (Egyptian fruit bat), Stomoxys calcitrans (barn fly), Terriglobus saanensis, Tolypocladium ophioglossoides, and Tolypocladium ophioglossoides CBS 100239. Also included are chimeras of two or more uricase polypeptides (e.g., the pig-baboon chimeric polypeptide included in pegloticase), as well as any homologs (as defined herein) thereof. Exemplary uricase polypeptide amino acid sequences include SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO:4.

[0135] In some optional embodiments described herein, the modified uricase comprises at least one polypeptide having the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, and / or SEQ ID NO: 3, and / or homologs thereof (as defined herein). As exemplified herein, such sequences may optionally be associated with relatively low polypeptide immunogenicity.

[0136] In some optional embodiments described herein, the modified uricase comprises at least one polypeptide having the amino acid sequence of SEQ ID NO: 1 and / or SEQ ID NO: 2, and / or homologs thereof (as defined herein). As exemplified herein, such sequences may optionally be associated with relatively low immunogenicity, a relatively high ability to undergo cross-linking (e.g., due to a large number of lysine residues in the sequence), and / or a relatively high stability under physiological conditions (e.g., thermostability at a temperature of about 37° C.).

[0137] Throughout this specification, a "homolog" of a given polypeptide (e.g., a uricase polypeptide described herein) refers to a polypeptide that exhibits at least 80% homology to the given polypeptide, preferably at least 90% homology, more preferably at least 95% homology, and more preferably at least 98% homology. In some embodiments, a homolog of a given polypeptide further shares an enzymatic activity and / or therapeutic activity (e.g., uric acid oxidation) with the given polypeptide. The percentage of homology refers to the percentage of amino acid residues in a first polypeptide sequence that match the corresponding residues in a second polypeptide sequence compared to the first polypeptide. Generally, polypeptides are aligned to maximize homology. Various strategies for performing amino acid or nucleotide sequence comparisons to assess the degree of identity are known in the art, including, for example, manual alignment, computer-assisted sequence alignment, and combinations thereof. Numerous algorithms (typically computer-implemented) for performing sequence alignment are widely available or can be created by those skilled in the art. Representative algorithms include, for example, the local homology algorithm of Smith and Waterman (Adv. Appl. Math., 1981, 2:482), the homology alignment algorithm of Needleman and Wunsch (J. Mol. Biol., 1970, 48:443), the similarity search method of Pearson and Lipman (Proc. Natl. Acad. Sci. (USA), 1988, 85:2444), and / or computer implementations of these algorithms (e.g., GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Drive, Madison, Wis.). Readily available computer programs incorporating such algorithms include, for example, BLASTN, BLASTP, Gapped BLAST, PILEUP, and CLUSTALW.When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs may be used, or alternatively, non-default parameters may be used by the practitioner based on experience and / or other requirements (see, for example, the website at URL www(dot)ncbi(dot)nlm(dot)nih(dot)gov).

[0138] In some optional embodiments relating to homologs of a given polypeptide, the homologs exhibit at least 80% sequence homology to the given polypeptide, optionally at least 90% sequence homology, optionally at least 95% sequence homology, optionally at least 98% sequence homology, and optionally at least 99% sequence homology.

[0139] In some optional embodiments described herein, the uricase polypeptide has the amino acid sequence of SEQ ID NO: 2. In some such embodiments, the modified uricase comprises multiple polypeptides having SEQ ID NO: 2, optionally four polypeptides having SEQ ID NO: 2.

[0140] As discussed in the Examples section below, SEQ ID NO:2 corresponds to a naturally occurring uricase polypeptide from Candida utilis (SEQ ID NO:1) with the point mutation C250K (i.e., Cys250 is replaced by lysine). The polypeptide of SEQ ID NO:2, like the polypeptide of SEQ ID NO:1, readily forms tetramers.

[0141] Alternatively, the uricase polypeptide may optionally be a homolog of SEQ ID NO:2, which homolog has any residue other than Cys at the position homologous to Lys250 of SEQ ID NO:2 (or Cys250 of SEQ ID NO:1). Optionally, the homolog contains a Lys at the position homologous to Lys250 of SEQ ID NO:2.

[0142] Without being bound by any particular theory, it is believed that Cys250 plays an important role in polypeptide aggregation by forming an intermolecular disulfide bond, and therefore removal of Cys250 significantly reduces undesired aggregation. Furthermore, the additional lysine residue (from the C250K mutation) is believed to facilitate cross-linking, e.g., with cross-linking moieties suitable for binding to amine groups.

[0143] According to an aspect of some embodiments of the present invention there is provided a polypeptide having the amino acid sequence of SEQ ID NO:2.

[0144] The uricase polypeptide of any of the embodiments of the present invention may optionally be purified (e.g., from plant or animal tissue) or produced by recombinant DNA technology. In any of several individual embodiments, the uricase polypeptide is a plant recombinant polypeptide, i.e., produced by recombinant technology in a plant. An example of a plant that produces recombinant forms of the polypeptide is Nicotiana tabacum (tobacco).

[0145] A wide variety of techniques are known in the art for the recombinant production of polypeptides in various cells and / or organisms, including plants and plant cells.

[0146] A recombinant protein may optionally be characterized by post-translational modifications (e.g., glycosylation) that are characteristic of the type of cell and / or organism (e.g., plant) in which the recombinant protein is produced, as opposed to, for example, the type of cell and / or organism that naturally expresses the polypeptide (or its closest naturally occurring homolog).

[0147] As used herein, the term "plant" includes whole plants, grafted plants, plant ancestors and progeny, and plant parts including seeds, shoots, stems, roots (including tubers), rootstocks, scions, and plant cells, tissues, and organs. Plants may be in any form, including suspension cultures, embryos, meristematic regions, callus tissue, leaves, gametophytes, sporophytes, pollen, and microspores. Plants that are particularly useful in the method of the present invention include all plants belonging to the superfamily Chlorophyta, especially monocotyledons and dicotyledons, including fodder or forage legumes, ornamentals, food crops, trees, or shrubs, such as Acacia spp., Acer spp., Actinidia spp., Aesculus spp., Agathis australis, Albizia amara, Alsophila tricolor, Andropogon spp., Arachis spp., Areca catechu, Astelia fragrans, Astragalus cicer, Baikiaea plurijuga, Betula spp., Brassica spp., Bruguiera gymnorrhiza, Burkea africana, Butea frondosa, Cadaba farinosa, Calliandra spp., Camellia sinensis, Cannabaceae, Cannabis indica, Cannabis, Cannabis sativa, Hemp, Industrial hemp, Capsicum spp., Cassia spp., Centroema pubescens, Chacoomeles spp., Cinnamomum cassia, Coffea arabica, Colophospermum mopane, Coronallia varia, Cotoneaster serotina, Crataegus spp., Cucumis spp., Cupressus spp., Cyathea dealbata, Cydonia oblonga, Cryptomeria japonica, Cymbopogon spp., Cynthea dealbata, Cydonia oblonga, Dalbergia monetaria, Davallia divaricata, Desmodium spp., Dicksonia squarosa, Dibeteropogon amplectens, Dioclea spp., Dolichos spp., Dorycnium rectum, Echinochloa pyramidalis, Ehraffia spp., Eleusine coracana, Eragrestis spp., Erythrina spp., Eucalyptus spp., Euclea schimperi, Eulalia villosa, Pagopyrum spp., Feijoa sellowlana, Fragaria spp., Flemingia spp., Freycinetia banksli, Geranium thunbergii, Ginkgo biloba, Glycine javanica, Gliricidia spp., Gossypium hirsutum, Grevillea spp., Guibourtia coleosperma, Hedysarum spp., Hemaffhia altissima, Heteropogon contoffus, Hordeum vulgare, Hyparrhenia rufa, Hypericum erectum, Hypeffhelia dissolute, Indigo incamata, Iris spp., Leptarrhena pyrolifolia, Lespediza spp., Lettuca spp., Leucaena leucocephala, Loudetia simplex, Lotonus bainesli, Lotus spp., Macrotyloma axillare, Malus spp., Manihot esculenta, Medicago saliva, Metasequoia glyptostroboides, Musa sapientum, Nicotianum spp., Onobrychis spp., Ornithopus spp., Oryza spp., Peltophorum africanum, Pennisetum spp., Persea gratissima, Petunia spp., Phaseolus spp., Phoenix canariensis, Phormium cookianum, Photinia spp., Picea glauca, Pinus spp., Pisum sativam, Podocarpus totara, Pogonarthria fleckii, Pogonaffhria squarrosa, Populus spp., Prosopis cineraria, Pseudotsuga menziesii, Pterolobium stellatum, Pyrus communis, Quercus spp., Rhaphiolepsis umbellata, Rhopalostylis sapida, Rhus natalensis, Ribes grossularia, Ribes spp., Robinia pseudoacacia, Rosa spp., Rubus spp., Salix spp., Schyzachyrium sanguineum, Sciadopitys vefficillata, Sequoia sempervirens, Sequoiadendron giganteum, Sorghum bicolor, Spinacia spp., Sporobolus fimbriatus, Stiburus alopecuroides, Stylosanthos humilis, Tadehagi spp., Taxodium distichum, Themeda triandra、Trifolium spp.、Triticum spp.、Tsuga heterophylla、Vaccinium spp.、Vicia spp., Vitis vinifera, Watsonia pyramidata, Zantedeschia aethiopica, corn, amaranth, artichoke, asparagus, broccoli, Brussels sprouts, cabbage, rapeseed, carrot, cauliflower, celery, collard greens, flax, kale, lentil, rapeseed, okra, onion, potato, rice, soybean, wheat, sugar beet, sugarcane, sunflower, tomato, squash, and / or trees. Alternatively, algae and other non-green plant subkingdoms can be used in the methods of some embodiments of the present invention.

[0148] Alternatively, the polypeptides of some embodiments of the present invention may be chemically synthesized by any technique known to those skilled in the art of peptide synthesis. For solid-phase peptide synthesis, overviews of many techniques can be found in J.M. Stewart and J.D. Young, "Solid Phase Peptide Synthesis," W.H. Freeman Co. (San Francisco), 1963, and J. Meienhofer, "Hormonal Proteins and Peptides," vol. 2, p. 46, Academic Press (New York), 1973. For classical solution synthesis, see G. Schroder and K. Lupke, "The Peptides," vol. 1, Academic Press (New York), 1965.

[0149] Generally, these methods involve the sequential addition of one or more amino acids or suitably protected amino acids to a growing polypeptide chain. Typically, either the amino or carboxyl group of the first amino acid is protected by a suitable protecting group. The protected or derivatized amino acid can then be attached to an inert solid support or utilized in solution by adding the next amino acid in the sequence, bearing a suitably protected complementary (amino or carboxyl) group, under conditions suitable for amide bond formation. The protecting group is then removed from this newly added amino acid residue, followed by the addition of the next amino acid (suitably protected), and so on. After all desired amino acids have been linked in the proper sequence, any remaining protecting groups (and any solid support) are removed sequentially or simultaneously to yield the final polypeptide compound. Simple modifications to this general procedure allow for the addition of more than one amino acid at a time to a growing chain, such as by coupling a protected tripeptide with a suitably protected dipeptide (under conditions that do not racemize the chiral centers) to form a pentapeptide after deprotection. Further description of peptide synthesis is provided in U.S. Pat. No. 6,472,505.

[0150] Large-scale polypeptide synthesis is described by Andersson et al. [Biopolymers 2000; 55:227-250].

[0151] As used herein, the term "polypeptide" refers to a polymer comprising at least 10 amino acid residues (preferably at least 50 amino acid residues) linked by peptide bonds or analogs thereof (described herein below), optionally exclusively by peptide bonds themselves. The term "polypeptide" encompasses naturally occurring polypeptides (e.g., degradation products, chemically synthesized peptides, and / or recombinant polypeptides), including, but not limited to, naturally occurring proteins, fragments of naturally occurring proteins, and homologs of naturally occurring proteins and / or fragments thereof, as well as peptidomimetics (typically chemically synthesized polypeptides) and polypeptide analogs, peptoids and semipeptoids, which may have modifications (e.g., modifications other than cross-linking modifications explicitly described herein) that, for example, render the polypeptide more stable in vivo or more permeable to cells. Such modifications include, but are not limited to, N-terminal modifications, C-terminal modifications, peptide bond modifications, backbone modifications, and residue modifications. Methods for preparing peptidomimetic compounds are well known in the art and are specified, for example, in Quantitative Drug Design, CA Ramsden Gd., Chapter 17.2, F. Choplin Pergamon Press (1992), which is incorporated by reference as if fully set forth herein. Further details in this regard are provided herein below.

[0152] The peptide bond (-CO-NH-) in a peptide may be replaced by, for example, an N-methylated amide bond (-N(CH3-CO-), an ester bond (-C(=O)-O-), a ketomethylene bond (-CO-CH2-), a sulfinylmethylene bond (-S(=O)-CH2-), an α-aza bond (-NH-N(R)-CO-), where R is any alkyl (e.g., methyl), an amine bond (-CH2-NH-), a sulfide bond (-CH2-S-), an ethylene bond (-CH2-CH2-), a hydroxyethylene bond (-CH(OH)-CH2-), a thioamide bond (-CS-NH-), an olefinic double bond (-CH=CH-), a fluorinated olefinic double bond (-CF=CH-), a retroamide bond (-NH-CO-), or a peptide derivative (-N(R)-CH2-CO-), and R is a "normal" side chain naturally occurring on a carbon atom.

[0153] These modifications can occur at any bond along the peptide chain, or even at several (eg, 2-3) bonds simultaneously.

[0154] The naturally occurring aromatic amino acids Trp, Tyr and Phe may be substituted with unnatural aromatic amino acids such as 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic), naphthylalanine, ring-methylated derivatives of Phe, halogenated derivatives of Phe or O-methyl-Tyr.

[0155] The peptides of some embodiments of the present invention may also include one or more modified amino acids or one or more non-amino acid monomers (eg, fatty acids, complex carbohydrates, etc.).

[0156] The term "amino acid" or "amino acids" is understood to include the 20 naturally occurring amino acids, amino acids that are often formed in vivo by post-translational modifications, such as hydroxyproline, phosphotyrosine, phosphothreonine, and other unconventional amino acids, such as, but not limited to, 2-aminodipic acid, hydroxylysine, isodesmosine, norvaline, norleucine, and ornithine. Furthermore, the term "amino acid" includes both D- and L-amino acids.

[0157] Tables 1 and 2 below list naturally occurring amino acids (Table 1) and unconventional or modified amino acids (eg, synthetic, Table 2) that may be used in some embodiments of the present invention.

[0158] [Table 1]

[0159] [Table 2-1]

[0160] [Table 2-2]

[0161] [Table 2-3]

[0162] Preparation of modified uricase: According to one aspect of some embodiments of the present invention, there is provided a method for preparing a modified uricase according to any of the embodiments relating to the modified uricase and / or components thereof (e.g., uricase polypeptide and / or linking moiety), the method comprising: (a) contacting a uricase polypeptide (according to any of the embodiments described herein) with a cross-linking agent (according to any of the embodiments described herein) comprising a poly(alkylene glycol) moiety to obtain a conjugate of the polypeptide and the cross-linking agent, wherein the cross-linking agent comprises at least two aldehyde (—C(═O)H) groups; and (b) contacting the conjugate with a reducing agent.

[0163] In any of several embodiments described herein, the cross-linking agent comprises no more than two aldehyde (—C(═O)H) groups.

[0164] In any of several embodiments described herein, the crosslinker is represented by Formula II: HC(=O)-L1-[O-(CH2)m]nO-L2-C(=O)H Formula II wherein L1 and L2 are hydrocarbon moieties, m is an integer ranging from 2 to 10, and n is an integer ranging from 2 to 1000 (e.g., wherein L1, L2, m, and / or n are as defined according to any of the embodiments described herein for Formula I). ​​The agent of Formula II may optionally be used to provide a linking moiety according to Formula I (according to any of the embodiments described herein), for example, by reacting each aldehyde group with an amine group (e.g., to form an imine or hemiaminal intermediate) and reducing to form an amine group.

[0165] Alternatively, the crosslinker may optionally contain three or more (e.g., three, four, or more) aldehyde groups. Such a crosslinker may optionally generate a bifunctional linking moiety (according to any of the embodiments described herein) by reacting only two of the aldehyde groups with a polypeptide, e.g., no unreacted amine group remains adjacent to the third aldehyde group upon reaction of the two aldehyde groups.

[0166] FIG. 1 illustrates a schematic diagram of a method according to any of several embodiments described herein.

[0167] Examples of suitable reducing agents include, but are not limited to, borane and its complexes (e.g., picoline borane complex), borohydrides (including borohydride salts, such as sodium borohydride), triacetoxyborohydrides (including triacetoxyborohydride salts, such as sodium triacetoxyborohydride), cyanoborohydrides (including cyanoborohydride salts, such as sodium cyanoborohydride), and any other reducing agent known in the art to be suitable for reductive amination processes. Exemplary reducing agents include, but are not limited to, 2-picoline borane complex and sodium cyanoborohydride.

[0168] The uricase polypeptide, crosslinking agent, and reducing agent may optionally be combined in any order. For example, the crosslinking agent may optionally be added to a mixture containing the polypeptide and reducing agent, or the polypeptide may optionally be added to a mixture containing the crosslinking agent and reducing agent (e.g., such that the conjugate of the polypeptide and crosslinking agent is already in contact with the reducing agent upon formation of the conjugate). In some embodiments, the uricase polypeptide, crosslinking agent, and reducing agent are combined essentially simultaneously (e.g., as a "one-pot reaction").

[0169] In any of several embodiments described herein, the uricase polypeptide is in a multimeric form (a form comprising two or more uricase polypeptide chains) when contacted with the cross-linking agent. Such a multimeric form may be, for example, a dimer, trimer, tetramer, hexamer, octamer, or a larger multimeric form. In some such embodiments, the multimeric form is a naturally occurring form of the uricase polypeptide, e.g., a tetramer for many uricase polypeptides. In any of the embodiments, contacting a multimeric form of the uricase polypeptide with a cross-linking agent can serve as an efficient technique for generating intermolecular cross-links, resulting in one or more cross-linking moieties attached to different polypeptide chains (e.g., according to any of the embodiments described herein).

[0170] In any of several embodiments described herein, the molar ratio of cross-linking agent (according to any of several embodiments described herein) to uricase polypeptide (according to any of several embodiments described herein) contacted with the cross-linking agent is at least 100:1. In some such embodiments, the molar ratio is between 100:1 and 10,000:1. In some such embodiments, the molar ratio is between 100:1 and 5,000:1. In some embodiments, the molar ratio is between 100:1 and 2,000:1. In some embodiments, the molar ratio is between 100:1 and 1,000:1.

[0171] In any of several embodiments described herein, the molar ratio of cross-linking agent (according to any of several embodiments described herein) to uricase polypeptide (according to any of several embodiments described herein) contacted with the cross-linking agent is at least 200:1. In some such embodiments, the molar ratio is between 200:1 and 10,000:1. In some such embodiments, the molar ratio is between 200:1 and 5,000:1. In some embodiments, the molar ratio is between 200:1 and 2,000:1. In some embodiments, the molar ratio is between 200:1 and 1,000:1. Exemplary ratios include 200:1 and 1,000:1.

[0172] In any of several embodiments described herein, the molar ratio of cross-linking agent (according to any of several embodiments described herein) to uricase polypeptide (according to any of several embodiments described herein) contacted with the cross-linking agent is at least 500:1. In some such embodiments, the molar ratio is between 500:1 and 10,000:1. In some such embodiments, the molar ratio is between 500:1 and 5,000:1. In some embodiments, the molar ratio is between 500:1 and 2,000:1.

[0173] In any of several embodiments described herein, the molar ratio of cross-linking agent (according to any of several embodiments described herein) to uricase polypeptide (according to any of several embodiments described herein) contacted with the cross-linking agent is at least 1,000:1. In some such embodiments, the molar ratio is between 1,000:1 and 10,000:1. In some such embodiments, the molar ratio is between 1,000:1 and 5,000:1.

[0174] The molecular weight of the cross-linking agent may optionally be selected to result in a cross-linking moiety having a molecular weight according to any of the embodiments described herein for the molecular weight of the cross-linking moiety. The relationship between the molecular weight of a given cross-linking agent and the cross-linking moiety produced from that cross-linking agent in the methods described herein will be apparent to one of skill in the art. For example, a drug of Formula II typically comprises a moiety of Formula I (variable L , L2, m, and n are similarly defined) have a molecular weight 30 Da greater (e.g., essentially a rounding error for molecular weights greater than 1 kDa).

[0175] According to an aspect of some embodiments of the present invention there is provided a modified uricase obtainable by the methods described herein, any of the embodiments.

[0176] Formulations and Indications: The modified uricase according to any of the embodiments described herein may optionally be for use in treating a disease or disorder in which uricase activity is beneficial and / or for use in treating a disease or disorder associated with excessive uric acid levels.

[0177] According to an aspect of some embodiments of the present invention, there is provided the use of a modified uricase according to any of the embodiments described herein in the manufacture of a medicament for treating a disease or disorder in which uricase activity is beneficial.

[0178] According to an aspect of some embodiments of the present invention there is provided use of a modified uricase according to any of the embodiments described herein in the manufacture of a medicament for treating a disease or disorder associated with excessive uric acid levels.

[0179] According to an aspect of some embodiments of the present invention, there is provided a method of treating a disease or disorder in which uricase activity is beneficial, comprising administering to a subject in need thereof a therapeutically effective amount of a modified uricase according to any of the embodiments described herein.

[0180] According to an aspect of some embodiments of the present invention, there is provided a method of treating a disease or disorder associated with excessive uric acid levels, comprising administering to a subject in need thereof a therapeutically effective amount of a modified uricase according to any of the embodiments described herein.

[0181] Examples of conditions treatable by some embodiments (according to any of the aspects described herein) include, but are not limited to, gout, diabetes, kidney stones, tumor lysis syndrome, hemorrhagic shock, malaria, allergic inflammation, renal dysfunction, viral infections such as influenza and COVID-19 (e.g., excessive uric acid levels are associated with antiviral drugs such as favipiravir), acute gastroenteritis, placentitis, sterile inflammation and other pregnancy complications related to uric acid (e.g., miscarriage, preeclampsia, and preterm birth), multiple sclerosis, inflammatory bowel disease, gastrointestinal infections, and Lesch-Nyhan syndrome.

[0182] In some optional embodiments described herein, the treatment promotes the dissolution of solid (e.g., crystalline) uric acid in the body, for example, in the treatment of gout, kidney stones, placentitis, sterile inflammation, pregnancy complications, Lesch-Nyhan syndrome, and / or tumor lysis syndrome.

[0183] In some optional embodiments described herein, treatment reduces the inflammatory effects of uric acid, which may optionally be beneficial in treating inflammatory conditions, such as gout, malaria, allergic inflammation, viral infections (e.g., COVID-19), acute gastroenteritis, placentitis, sterile inflammation, pregnancy complications, multiple sclerosis, and inflammatory bowel disease.

[0184] According to an aspect of some embodiments of the present invention, there is provided a method of reducing uric acid levels in a medium, the method comprising contacting the medium with a modified uricase according to any of the embodiments described herein. The medium may optionally be an in vivo or ex vivo physiological medium (e.g., tissue), or a non-physiological medium.

[0185] In some embodiments, the medium is tissue of a subject (human or non-human) in need thereof, and the method comprises administering modified uricase to the subject, who may optionally be suffering from or at risk of suffering from a disease or disorder according to any of the embodiments described herein.

[0186] The modified uricase according to any of the embodiments described herein can optionally be used by itself or alternatively as part of a pharmaceutical composition that further comprises a pharmaceutically acceptable carrier.

[0187] As used herein, "pharmaceutical composition" refers to a preparation of one or more modified uricases described herein that is pharmaceutically acceptable and includes other chemical components, such as suitable carriers and additives. The purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.

[0188] Hereinafter, the term "pharmaceutically acceptable carrier" refers to a carrier or diluent that does not cause significant irritation to an organism and does not abolish the biological activity and properties of the administered compound. Examples of carriers include, but are not limited to, propylene glycol, saline, emulsions and mixtures of organic solvents and water, as well as solid (e.g., powdered) and gaseous carriers.

[0189] As used herein, the term "excipient" refers to an inert substance added to a pharmaceutical composition to further facilitate administration of a compound. Examples of excipients include, but are not limited to, calcium carbonate, calcium phosphate, various types of sugars and starches, cellulose derivatives, gelatin, vegetable oils, and polymers such as polyethylene glycols.

[0190] Techniques for drug formulation and administration can be found in the latest edition of "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, PA, which is incorporated herein by reference.

[0191] The pharmaceutical compositions of the present invention may be manufactured by methods well known in the art, for example, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.

[0192] Thus, pharmaceutical compositions for use in accordance with the present invention may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers containing additives and adjuvants that facilitate processing of the modified uricase into pharmaceutically usable preparations. The appropriate formulation will vary depending on the route of administration selected.

[0193] The modified uricase described herein may be formulated for parenteral administration, for example, by bolus injection or continuous infusion. Formulations for injection or infusion may be provided in unit dosage form, for example, in ampoules or in multi-dose containers, optionally with an added preservative. The compositions may be suspensions, solutions, or emulsions in oily or aqueous vehicles and may contain formulatory agents such as suspending, stabilizing, and / or dispersing agents.

[0194] Pharmaceutical compositions for parenteral administration include aqueous solutions of the modified uricase preparation in water-soluble form. For injection or infusion, the modified uricase may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline buffer, optionally with or without organic solvents such as propylene glycol, polyethylene glycol.

[0195] Additionally, suspensions of the modified uricase may be prepared as appropriate oily injection suspensions and emulsions (e.g., water-in-oil, oil-in-water, or water-in-oil emulsions). Suitable lipophilic solvents or excipients include fatty oils such as sesame oil, or synthetic fatty acid esters such as ethyl oleate, triglycerides, or liposomes. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents that increase the solubility of the modified uricase to allow for the preparation of highly concentrated solutions.

[0196] Direct injection and / or infusion into the bloodstream (e.g., intravenous administration) may be particularly suitable for treating hyperuricemia, a condition in which blood levels of uric acid are elevated, including any conditions associated therewith. Administration into the bloodstream may also optionally be used to deliver the modified uricase to specific tissues.

[0197] Alternatively or additionally, modified uricase may be injected locally into a tissue with excessive uric acid levels, optionally a tissue associated with uric acid deposition, such as a joint (e.g., in the case of gout) or a kidney (e.g., in the case of kidney stones).

[0198] For transmucosal administration, penetrants are used in the formulation. Such penetrants are generally known in the art.

[0199] For oral administration, the modified uricase of the present invention can be easily formulated by combining the modified uricase with pharmaceutically acceptable carriers well known in the art. Such carriers allow the modified uricase described herein to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like for oral ingestion by patients. Pharmaceutical preparations for oral use can be made using solid additives, and the resulting mixture can be optionally milled and processed into tablets or dragee cores by adding suitable excipients as needed. Suitable additives include, inter alia, fillers such as sugars including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as corn starch, wheat starch, rice starch, potato starch, gelatin, tragacanth gum, methylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose; and / or physiologically acceptable polymers, such as polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.

[0200] The dragee core is provided with a suitable coating. For this purpose, concentrated sugar solutions, which may optionally contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures, can also be used. Dyes or pigments can be added to the tablets or dragee coatings for identification or to characterize different combinations of active modified uricase dosages.

[0201] Pharmaceutical compositions that can be used orally include push-fit capsules made of gelatin and soft, sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol. Push-fit capsules may contain the active ingredient mixed with a filler such as lactose, a binder such as starch, a lubricant such as talc or magnesium stearate, and optionally, a stabilizer. In soft capsules, the modified uricase may be dissolved or suspended in a suitable liquid such as fatty oils, liquid paraffin, or liquid polyethylene glycol. Additionally, stabilizers may be added. All formulations for oral administration should be in a dosage appropriate for the selected route of administration.

[0202] The modified uricase of embodiments of the present invention may also be formulated in rectal compositions such as suppositories or retention enemas, using, eg, conventional suppository bases such as cocoa butter or other glycerides.

[0203] Oral and / or rectal administration may be particularly suitable for treating diseases or disorders of the gastrointestinal tract, such as conditions associated with inflammation of the gastrointestinal tract (eg, inflammatory bowel disease and / or gastroenteritis).

[0204] For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

[0205] For administration by inhalation, the modified uricase is conveniently delivered in the form of an aerosol spray presentation (typically containing a powdered, liquefied, and / or gaseous carrier) from pressurized packs or nebulizer using a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane, or carbon dioxide. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin, for use in an inhaler or insufflator may be formulated containing a powder mix of the modified uricase and a suitable powder base, such as, but not limited to, lactose or starch.

[0206] Alternatively, the modified uricase may be in powder form for constitution with a suitable vehicle, eg, sterile pyrogen-free water, before use.

[0207] Pharmaceutical compositions suitable for use in the context of the present invention include compositions containing the active ingredients in an amount effective to achieve its intended purpose. More specifically, a therapeutically effective amount means an amount of modified uricase effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated.

[0208] For any modified uricase used in the methods of the invention, the therapeutically effective amount or dose can be estimated initially from animal activity assays. For example, the IC measured by the activity assay. 50 A dose can be formulated in animal models to achieve a circulating concentration range that includes (e.g., the concentration of the test protein structure that achieves a half-maximal increase in the biological activity of the modified uricase). Such information can be used to more accurately determine useful doses in humans.

[0209] As demonstrated in the Examples section below, a therapeutically effective amount of modified uricase according to embodiments of the present invention may range from about 1 μg / kg body weight to about 500 mg / kg body weight. In some optional embodiments described herein, the therapeutically effective amount of modified uricase is from about 10 μg / kg body weight to about 2000 μg / kg body weight, optionally from about 25 μg / kg body weight to about 800 μg / kg body weight.

[0210] The toxicity and therapeutic efficacy of the modified uricases described herein can be determined by standard pharmaceutical procedures in laboratory animals, e.g., by the EC 50 ,I C 50 and LD 50 The lethal dose (the dose that causes death in 50% of the test animals) can be determined by measuring the lethal dose. The data obtained from these activity assays and animal studies can be used in formulating a range of dosage for human use.

[0211] The dosage may vary depending on the dosage form used and the route of administration utilized. The exact formulation, route of administration, and dosage can be chosen by the individual physician in consideration of the patient's condition. (See, for example, Fingl et al., 1975, in "The Pharmacological Basis of Therapeutics," Ch. 1, p. 1.)

[0212] Dosage and interval can be individually adjusted to provide a plasma level of active uricase sufficient to maintain the desired effect, referred to as the minimum effective concentration (MEC). The MEC varies for each preparation but can be estimated from in vitro data, e.g., the concentration required to achieve the desired level of activity in vitro. The dosage required to achieve the MEC will vary depending on individual characteristics and the route of administration. Plasma concentrations can be measured using HPLC assays or bioassays.

[0213] Dosage intervals can also be determined using the MEC value. Formulations should be administered using a regimen that maintains plasma levels above the MEC for 10-90% of the time, preferably 30-90% of the time, and most preferably 50-90% of the time.

[0214] As discussed herein, the modified uricases described herein can exhibit long half-lives in the body. Such properties can allow for the use of relatively infrequent administration (which can be particularly advantageous when administration is by an inconvenient route, such as injection) and / or relatively low doses (which can be particularly advantageous in reducing toxicity and / or immune responses that may arise against the modified uricase).

[0215] Some conditions treatable by uricase activity may not require a continuous, long-term minimum effective concentration of modified uricase. Thus, the modified uricase may be administered less frequently than necessary to continuously provide the minimum effective concentration. For example, a condition characterized by uric acid precipitation may be treated by administering a sufficient amount of modified uricase to promote partial or complete dissolution of the precipitated uric acid in the body, followed by an interval during which uricase activity is not required, e.g., until sufficient time has passed for clinically significant levels of uric acid to be reprecipitated.

[0216] In some optional embodiments described herein, administration (e.g., by injection) occurs at least weekly (i.e., treatment includes multiple administrations separated by at least one week intervals), optionally up to six or twelve months (one year) apart. In some such embodiments, the interval is at least two weeks. In some embodiments, the interval is at least one month (e.g., between one and twelve months, or between one and six months, or between one and two months, optionally in the range of one or two months). In some embodiments, the interval is at least two months (e.g., between two and twelve months, or between two and six months). In some embodiments, the interval is at least three months (e.g., in the range of three to twelve months, or three to six months).

[0217] In some optional embodiments described herein, the dosing frequency and dose per administration are selected so that the administered dose of modified uricase (e.g., by injection in an adult subject) is 60 mg / month or less of modified uricase (e.g., 120 mg administered every three months is considered a 40 mg / month dose). In some such embodiments, the dosage is 40 mg / month or less (e.g., 80 mg or less administered about every two months). In some such embodiments, the dosage is 24 mg / month or less (e.g., 48 mg or less administered about every two months). In some such embodiments, the dosage is 16 mg / month or less (e.g., 32 mg or less administered about every two months). In some such embodiments, the dosage is 12 mg / month or less (e.g., 24 mg or less administered about every two months). In some such embodiments, the dosage is 10 mg / month or less (e.g., 20 mg or less administered about every two months). In some embodiments, the dosage is 8 mg / month or less (e.g., 16 mg or less administered about every two months). In some embodiments, the dosage is 6 mg / month or less (e.g., 12 mg or less administered about every two months). In some embodiments, the dosage is 4 mg / month or less (e.g., 8 mg or less administered about every two months). In some embodiments, the dosage is 2 mg / month or less. In some embodiments, the dosage is 1 mg / month or less.

[0218] In some optional embodiments described herein, the dosing frequency and dosage per administration are selected so that the administered dose of modified uricase is 2 mg / kg body weight / month or less of modified uricase. In some such embodiments, the dosage is 0.8 mg / kg body weight / month or less (e.g., 1.6 mg / kg body weight or less administered about every two months). In some such embodiments, the dosage is 0.4 mg / kg body weight / month or less (e.g., 0.8 mg / kg body weight or less administered about every two months). In some such embodiments, the dosage is 0.2 mg / kg body weight / month or less (e.g., 0.4 mg / kg body weight or less administered about every two months). In some such embodiments, the dosage is 0.1 mg / kg body weight / month or less (e.g., 0.2 mg or less administered about every two months). In some embodiments, the dosage is 0.5 mg / kg body weight / month or less. In some embodiments, the dosage is 0.25 mg / kg body weight / month or less.

[0219] Depending on the severity and responsiveness of the condition to be treated, administration may also optionally be a single dose of a sustained release composition as described herein above, with the course of treatment lasting from several days to several weeks, or until a cure is effected or a diminution of the disease state is achieved.

[0220] The amount of composition administered will, of course, be dependent on the subject being treated, the severity of the affliction, the manner of administration, and the judgment of the prescribing physician.

[0221] Compositions of the invention may, if desired, be presented in a pack or dispenser device, such as an FDA (U.S. Food and Drug Administration) approved kit, which may contain one or more unit dosage forms containing the active ingredient. The pack may, for example, but not limited to, comprise metal or plastic foil, such as a blister pack or a pressurized container (for inhalation). The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser may also be accompanied by a notice associated with the container in a form prescribed by a government agency regulating the manufacture, use, or sale of pharmaceuticals, reflecting approval by that agency of the composition form for human or veterinary administration. Such notice may, for example, be a label approved by the U.S. Food and Drug Administration for prescription drugs or a product insert. Compositions comprising the modified uricase of any of the embodiments of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment or diagnosis of an indicated condition, as detailed herein.

[0222] Thus, according to one embodiment of the present invention, the pharmaceutical compositions described herein are packaged in packaging material and identified by printing in or on the packaging material for use in the treatment of a condition in which the activity of modified uricase is beneficial, as described herein above.

[0223] Additional definitions: As used herein, the terms "hydrocarbon" and "hydrocarbon moiety" refer to an organic moiety that contains as its backbone a chain of carbon atoms substituted primarily by hydrogen atoms. The hydrocarbon may be saturated or unsaturated, may be composed of aliphatic, alicyclic, or aromatic moieties, and may optionally be substituted by one or more substituents (other than hydrogen). The substituted hydrocarbon may have one or more substituents, each of which may independently be, for example, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, amine, halo, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, sulfonate, sulfate, cyano, nitro, azido, phosphonyl, phosphinyl, oxo, carbonyl, thiocarbonyl, urea, thiourea, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, S-thiocarbamyl, C-amido, N-amido, C-carboxy, O-carboxy, sulfonamido, guanyl, guanidinyl, hydrazine, hydrazide, thiohydrazide, and amino. The hydrocarbon may be a terminal group or a linking group, as these terms are defined herein. Preferably, the hydrocarbon moiety has 1 to 20 carbon atoms. When a numerical range is given herein, for example, "1 to 20," this means that the hydrocarbon can contain up to 20 carbon atoms, such as 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc. Optionally, the hydrocarbon can be a medium-sized hydrocarbon having 1 to 10 carbon atoms. Optionally, the hydrocarbon has 1 to 4 carbon atoms.

[0224] As used herein, the phrase "linking group" refers to a group (e.g., a substituent) that is attached to two or more moieties in a compound, while the phrase "terminal group" refers to a group (e.g., a substituent) that is attached to a single moiety in a compound through one of its atoms.

[0225] As used throughout this specification, the term "alkyl" refers to any saturated aliphatic hydrocarbon, including straight-chain and branched-chain groups. Preferably, the alkyl group has 1 to 20 carbon atoms. More preferably, the alkyl is a medium-sized alkyl having 1 to 10 carbon atoms. Most preferably, unless otherwise indicated, the alkyl is a lower alkyl having 1 to 4 carbon atoms. The alkyl group may be substituted or unsubstituted.

[0226] When substituted, the substituent can be, for example, cycloalkyl, aryl, heteroaryl, heteroalicyclic, halo, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, sulfonate, sulfate, cyano, nitro, azido, phosphonyl, phosphinyl, oxo, carbonyl, thiocarbonyl, urea, thiourea, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, S-thiocarbamyl, C-amido, N-amido, C-carboxy, O-carboxy, sulfonamido, guanyl, guanidinyl, hydrazine, hydrazide, thiohydrazide, and amino, as these terms are defined herein.

[0227] As used herein, the term "alkenyl" refers to an unsaturated aliphatic hydrocarbon containing at least one carbon-carbon double bond, including straight-chain and branched-chain groups. Preferably, the alkenyl group has 2 to 20 carbon atoms. More preferably, the alkenyl is a medium-sized alkenyl having 2 to 10 carbon atoms. Most preferably, unless otherwise specified, the alkenyl is a lower alkenyl having 2 to 4 carbon atoms. The alkenyl group may be substituted or unsubstituted.

[0228] A substituted alkenyl can have one or more substituents, each of which can independently be, for example, alkynyl, cycloalkyl, alkynyl, aryl, heteroaryl, heteroalicyclic, halo, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, sulfonate, sulfate, cyano, nitro, azido, phosphonyl, phosphinyl, oxo, carbonyl, thiocarbonyl, urea, thiourea, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, S-thiocarbamyl, C-amido, N-amido, C-carboxy, O-carboxy, sulfonamido, guanyl, guanidinyl, hydrazine, hydrazide, thiohydrazide, and amino.

[0229] As used herein, the term "alkynyl" refers to an unsaturated aliphatic hydrocarbon containing at least one carbon-carbon triple bond, including straight-chain and branched-chain groups. Preferably, the alkynyl group has 2 to 20 carbon atoms. More preferably, the alkynyl is a medium-sized alkynyl having 2 to 10 carbon atoms. Most preferably, unless otherwise specified, the alkynyl is a lower alkynyl having 2 to 4 carbon atoms. The alkynyl group may be substituted or unsubstituted.

[0230] A substituted alkynyl can have one or more substituents, each of which can independently be, for example, cycloalkyl, alkenyl, aryl, heteroaryl, heteroalicyclic, halo, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, sulfonate, sulfate, cyano, nitro, azido, phosphonyl, phosphinyl, oxo, carbonyl, thiocarbonyl, urea, thiourea, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, S-thiocarbamyl, C-amido, N-amido, C-carboxy, O-carboxy, sulfonamido, guanyl, guanidinyl, hydrazine, hydrazide, thiohydrazide, and amino.

[0231] The term "alkylene" refers to a saturated or unsaturated aliphatic hydrocarbon linking group, as defined herein, and differs from an alkyl group (if saturated) or an alkenyl or alkynyl group (if unsaturated), as defined herein, only in that the alkylene is a linking group rather than a terminal group.

[0232] A "cycloalkyl" group refers to a saturated group on an unsaturated all-carbon monocyclic or fused ring system (i.e., rings that share adjacent pairs of carbon atoms) in which one or more rings do not have a fully conjugated pi-electron system. Examples of cycloalkyl groups include, but are not limited to, cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexadiene, cycloheptane, cycloheptatriene, and adamantane. Cycloalkyl groups can be substituted or unsubstituted. When substituted, the substituents can be, for example, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, halo, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, sulfonate, sulfate, cyano, nitro, azido, phosphonyl, phosphinyl, oxo, carbonyl, thiocarbonyl, urea, thiourea, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, S-thiocarbamyl, C-amido, N-amido, C-carboxy, O-carboxy, sulfonamido, guanyl, guanidinyl, hydrazine, hydrazide, thiohydrazide, and amino, as these terms are defined herein. When a cycloalkyl group is unsaturated, the cycloalkyl group can contain at least one carbon-carbon double bond and / or at least one carbon-carbon triple bond. A cycloalkyl group, as this term is defined herein, can be a terminal group attached to a single adjacent atom, or a linking group, as this term is defined herein, connecting two or more moieties.

[0233] An "aryl" group refers to an all-carbon monocyclic or fused-ring polycyclic (i.e., rings that share adjacent pairs of carbon atoms) terminal group having a fully conjugated pi-electron system. Examples of aryl groups include, but are not limited to, phenyl, naphthalenyl, and anthracenyl. Aryl groups may be substituted or unsubstituted. When substituted, the substituent can be, for example, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, halo, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, sulfonate, sulfate, cyano, nitro, azido, phosphonyl, phosphinyl, oxo, carbonyl, thiocarbonyl, urea, thiourea, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, S-thiocarbamyl, C-amido, N-amido, C-carboxy, O-carboxy, sulfonamido, guanyl, guanidinyl, hydrazine, hydrazide, thiohydrazide, and amino, as these terms are defined herein.

[0234] A "heteroaryl" group refers to a monocyclic or fused ring (i.e., rings sharing adjacent pairs of atoms) terminal group having one or more atoms in the ring, such as nitrogen, oxygen, and sulfur, and further having a fully conjugated pi-electron system. Examples of heteroaryl groups include, but are not limited to, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrimidine, quinoline, isoquinoline, and purine. Heteroaryl groups may be substituted or unsubstituted. When substituted, the substituent can be, for example, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, halo, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, sulfonate, sulfate, cyano, nitro, azido, phosphonyl, phosphinyl, oxo, carbonyl, thiocarbonyl, urea, thiourea, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, S-thiocarbamyl, C-amido, N-amido, C-carboxy, O-carboxy, sulfonamido, guanyl, guanidinyl, hydrazine, hydrazide, thiohydrazide, and amino, as these terms are defined herein.

[0235] The term "arylene," as defined herein, represents a monocyclic or fused-ring polycyclic linking group and encompasses linking groups that differ from aryl or heteroaryl groups only in that an arylene, as defined herein, is a linking group rather than a terminal group.

[0236] A "heteroalicyclic" group refers to a monocyclic or fused ring group having one or more atoms, such as nitrogen, oxygen, and sulfur, in the ring. The ring may also have one or more double bonds. However, the ring does not have a completely conjugated π-electron system. A heteroalicyclic group may be substituted or unsubstituted. When substituted, the substituent may be, for example, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, halo, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, sulfonate, sulfate, cyano, nitro, azido, phosphonyl, phosphinyl, oxo, carbonyl, thiocarbonyl, urea group, thiourea group, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, S-thiocarbamyl, C-amide, N-amide, C-carboxy, O-carboxy, sulfonamide, guanyl, guanidinyl, hydrazine, hydrazide, thiohydrazide and amino, where these terms are as defined herein.Representative examples include piperidine, piperazine, tetrahydrofuran, tetrahydropyran, morpholine, etc. A heteroalicyclic group may be a terminal group, as defined herein, attached to a single adjacent atom, or a linking group, as defined herein, joining two or more moieties.

[0237] As used herein, the terms "amine" and "amino" refer to the group -NR'R'' or -N +"R" refers to any of the R'R"R'" groups, where R', R" and R"' each is hydrogen or substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroalicyclic (bonded to the amine nitrogen through a ring carbon thereof), aryl, or heteroaryl (bonded to the amine nitrogen through a ring carbon thereof), as defined herein. Optionally, R', R" and R'" are hydrogen or alkyl containing 1 to 4 carbon atoms. Optionally, R' and R" (and R'" if present) are hydrogen. If substituted, the carbon atom of the R', R" or R'" hydrocarbon portion bonded to the nitrogen atom of the amine is not substituted with oxo (unless otherwise specified), and R', R" and R'" are not (for example) carbonyl, C-carboxy, or amido, as these groups are defined herein.

[0238] An "azido" group is -N=N + =N - Refers to the base.

[0239] An "alkoxy" group refers to both an --O-alkyl group and an --O-cycloalkyl group, as defined herein.

[0240] An "aryloxy" group refers to both an --O-aryl and an --O-heteroaryl group, as defined herein.

[0241] A "hydroxy" group refers to an --OH group.

[0242] A "thiohydroxy" or "thiol" group refers to a --SH group.

[0243] A "thioalkoxy" group refers to both an --S-alkyl group and an --S-cycloalkyl group, as defined herein.

[0244] A "thioaryloxy" group refers to both an --S-aryl and an --S-heteroaryl group, as defined herein.

[0245] A "carbonyl" group refers to either a -C(=O)-R' terminal group, where R' is defined above, or a -C(=O)- linking group.

[0246] An "aldehyde" group refers to a -C(=O)H group.

[0247] A "thiocarbonyl" group refers to a -C(=S)-R' group, where R' is as defined herein.

[0248] "Carboxyl," "carboxy," or "carboxylate" refers to both a "C-carboxy" and an "O-carboxy" group as defined herein.

[0249] A "C-carboxy" group refers to a -C(=O)-O-R' group, where R' is as defined herein.

[0250] An "O-carboxy" group refers to an R'C(=O)-O group, where R' is as defined herein.

[0251] An "oxo" group refers to a =O group.

[0252] A "halo" group refers to fluorine, chlorine, bromine or iodine.

[0253] A "sulfinyl" group refers to a -S(=O)-R' group, where R' is as defined herein.

[0254] A "sulfonyl" group refers to a -S(=O)2-R' group, where R' is as defined herein.

[0255] A "sulfonate" group refers to a -S(=O)2-O-R' group, where R' is as defined herein.

[0256] A "sulfate" group refers to an -OS(=O)2-O-R' group, where R' is as defined herein.

[0257] A "sulfonamide" or "sulfonamido" group includes both S- and N-sulfonamido groups as defined herein.

[0258] An "S-sulfonamido" group refers to a -S(=O)2-NR'R'' group, where each of R' and R'' are as defined herein.

[0259] An "N-sulfonamido" group refers to an R'S(=O)2-NR'' group, where R' and R'' are as defined herein.

[0260] An "O-carbamyl" group refers to an --O--C(.dbd.O)--NR'R'' group, where each of R' and R'' are as defined herein.

[0261] An "N-carbamyl" group refers to an R'OC(=O)-NR''- group, where each of R' and R'' are as defined herein.

[0262] An "O-thiocarbamyl" group refers to an --OC(.dbd.S)--NR'R'' group, where each of R' and R'' are as defined herein.

[0263] An "N-thiocarbamyl" group refers to an R'OC(=S)NR''- group, where R' and R'' are as defined herein.

[0264] An "S-thiocarbamyl" group refers to a -SC(=O)-NR'R'' group, where each of R' and R'' are as defined herein.

[0265] An "amide" or "amido" group includes C-amido and N-amido groups as defined herein.

[0266] A "C-amido" group refers to a -C(=O)-NR'R'' group, where each of R' and R'' are as defined herein.

[0267] An "N-amido" group refers to an R'C(=O)-NR''- group, where R' and R'' are as defined herein.

[0268] A "urea group" refers to a -N(R')-C(=O)-NR''R''' group, where R', R'', and R'' are as defined herein.

[0269] A "thiourea group" refers to a -N(R')-C(=S)-NR''R''' group, where R', R'', and R'' are as defined herein.

[0270] A "nitro" group refers to a -NO2 group.

[0271] A "cyano" group refers to a -C≡N group.

[0272] The term "phosphonyl" or "phosphonate" refers to a -P(=O)(OR')(OR'') group, where R' and R'' are as defined hereinabove.

[0273] The term "phosphate" refers to the group --OP(.dbd.O)(OR')(OR''), where each of R' and R'' is as defined hereinabove.

[0274] The term "phosphinyl" refers to the group -PR'R'' where each of R' and R'' are as defined hereinabove.

[0275] The term "hydrazine" refers to the group -NR'-NR''R''', where R', R'', and R''' are as defined herein.

[0276] As used herein, the term "hydrazide" refers to the group -C(=O)-NR'-NR''R'' where R', R'' and R''' are as defined herein.

[0277] As used herein, the term "thiohydrazide" refers to the group -C(=S)-NR'-NR''R'' where R', R'' and R''' are as defined herein.

[0278] A "guanidinyl" group refers to a -RaNC(=NRd)-NRbRc group, where each of Ra, Rb, Rc, and Rd can be as defined herein for R' and R''.

[0279] A "guanyl" or "guanine" group refers to a R aR bNC(=NR d )- group, where R a, R b , and R d are as defined herein.

[0280] "Imine" refers to the group -C(=NR'')-R', where R' and R'' are as defined herein above.

[0281] A "hemiaminal" refers to a -C(R')(OH)-NR''R''' group, where R', R'', and R''' are as defined herein.

[0282] As used herein, the term "about" refers to ±10% or ±5%.

[0283] The words "comprises," "comprising," "includes," "including," "having," and conjugations thereof mean "including but not limited to."

[0284] The term "consisting of" means "including and limited to."

[0285] The term "consisting essentially of" means that a composition, method, or structure may include additional components, steps, and / or moieties, but only if the additional components, steps, and / or moieties do not materially alter the basic and novel characteristics of the claimed composition, method, or structure.

[0286] As used herein, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise. For example, "a compound" or "at least one compound" includes multiple compounds and may also include mixtures thereof.

[0287] Throughout this application, various embodiments of the invention may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to specifically disclose all of the possible subranges and individual numerical values ​​within that range. For example, the description of a range such as 1 to 6 should be considered to specifically disclose subranges such as 1 to 3, 1 to 4, 1 to 5, 2 to 4, 2 to 6, 3 to 6, etc., as well as individual numerical values ​​within that range, e.g., 1, 2, 3, 4, 5, and 6. This applies regardless of the magnitude of the range.

[0288] Whenever a range of numerical values ​​is given herein, it is intended to include any recited number (fractional or integer) within the range given. The phrases "ranging between" a first indicated number and a second indicated number and "ranging from" a first indicated number to a second indicated number are used interchangeably herein and are intended to include the first indicated number and the second indicated number, and all fractional and integer numbers between the first indicated number and the second indicated number.

[0289] As used herein, the term "method" means manner, means, techniques, and procedures for accomplishing a given task, including, but not limited to, those known to practitioners in the fields of chemistry, pharmacology, biology, biochemistry, and medicine or those that can be readily developed by practitioners from known manners, means, techniques, and procedures.

[0290] It will be understood that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, multiple features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination, or with respect to any other described embodiment of the invention, as appropriate. A particular feature described in the context of various embodiments should not be considered an essential feature of that embodiment, unless the embodiment is inoperable without that element.

[0291] Various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below find experimental support in the following examples. [Example]

[0292] Reference is now made to the following examples, which together with the above descriptions, illustrate some embodiments of the present invention in a non-limiting fashion.

[0293] Materials and Methods material: Chimeric cHu3.3 human anti-PEG IgG1 antibody was obtained from Academia Sinica (Taiwan).

[0294] 2-Picoline borane and sodium cyanoborohydride (NaBH3CN) were obtained from Sigma Aldrich.

[0295] Monofunctional polyethylene glycol nitrophenyl carbonate (mPEG(10K)-NPC) was obtained from Creative PEGWorks.

[0296] Polyethylene glycol bisaldehyde (bis-Ald-PEG) reagent was obtained from Creative PEGWorks.

[0297] Polyethylene glycol bis-N-hydroxysuccinimide (2 kDa) (bis-NHS-PEG2000) was obtained from Iris Biotech Gmbh.

[0298] Construction of vectors for expressing uricase variants in BY2 cells: For transformation and expression of different uricase sequences in BY2 cells, an expression system based on the geminivirus Bean Yellow Dwarf Virus (BeYDV) replicon [Chen et al., Hum Vaccin 2011, 7:331-338; Mor et al., Biotechnol Bioeng 2003, 81:430-437] was used.

[0299] Transformation of BY2 cells, expression of uricase and isolation of selected strains: Genetic transformation of BY2 cells with the above molecular constructs was performed using the Agrobacterium-mediated transformation procedure described by An et al. [EMBO J 1985, 4:277-284]. Transformed cells were selected using kanamycin as the selective agent. Once a viable, kanamycin-resistant cell suspension was generated, it was used to isolate and screen individual cell lines (clones). Individual cell lines were established by spreading highly diluted aliquots of the transgenic cell suspension onto solid medium. Cells were grown until small calli (plant cell masses) developed. Each calli, representing a single clone, was then resuspended in liquid medium and sampled. Individual transformed cell lines were isolated and screened for uricase expression levels. The line showing the highest expression level was selected for further process development.

[0300] Plant cell suspension: N. tabacum cv. BY2 cells were grown as suspension cultures in liquid MS-BY2 medium [Nagata & Kumagai, Methods Cell Sci 1999, 21:123-127] at 25°C with constant agitation (85 rpm) on an orbital shaker. The suspension was grown in 250 mL Erlenmeyer flasks at a volume of 50 mL and subcultured weekly at a concentration of 2.5% (v / v).

[0301] Preparation of "pegloticase-like" PEGylated uricase: For use as a "pegloticase-like" control, monofunctional PEG-modified uricase was prepared by diluting prU-C250K uricase (SEQ ID NO: 2) to 1 mg / mL in 100 mM phosphate buffer (pH 8) and adding 1,000 molar equivalents of monofunctional polyethylene glycol nitrophenyl carbonate. The reaction proceeded for 2 hours at room temperature. Purification was performed by three cycles of dialysis against 100 mM phosphate buffer (pH 8) using an Amicon® system with a 100K cutoff (14,000 G, 4 minutes).

[0302] Assessment of antibody levels by ELISA: MaxiSorp™ 96-well microtiter plates were coated with 5 μg / mL uricase samples in phosphate-buffered saline, incubated overnight at 4°C, washed, and blocked with 2% bovine serum albumin for 2 hours at room temperature. The plates were then washed to remove unbound protein, and 100 μL of serum was added. After a further incubation of 2 hours at room temperature with shaking at 600 rpm, unbound compound was washed away, and mouse anti-human IgG-alkaline phosphatase was added to each well at a 1:5000 dilution and incubated for 1.5 hours at room temperature with shaking at 600 rpm. After a final washing step, BluePhos® phosphatase substrate was added, and the reaction was stopped with alkaline phosphatase stop solution. Final absorbance was measured at 630 nm using a microplate reader (Tecan).

[0303] MALDI-TOF mass spectrometry: Sample preparation: A matrix solution was prepared by mixing 375 μL of a 20 mg / mL 2,5-DHAP (2,5-dihydroxyacetophenone) ethanol solution with 125 μL of an 18 mg / mL DAC (diammonium hydrogen citrate) aqueous solution. 2 μL of the sample solution was mixed with 2 μL of a 2% trifluoroacetic acid solution, followed by 2 μL of the matrix solution. The resulting three-component mixture was pipetted up and down. The initially clear mixture became opaque as crystallization began. A 0.5 μL volume of this mixture was applied to a MALDI steel target plate. After the solvent evaporated, the target plate was inserted into the mass spectrometer.

[0304] Mass spectrometry: MALDI-TOF mass spectra were acquired using a MALDI-TOF / TOF Autolex™ velocity mass spectrometer (Bruker Daltonik GmbH). The mass spectrometer was equipped with a SmartBeam™ II solid-state laser (modified Nd:YAG laser; λ = 355 nm) and operated in linear mode for positive ions within the m / z range of 20,000–200,000 or 60,000–200,000. The laser fluence was optimized for each sample. The laser was operated at a frequency of 2 kHz, and spectra were accumulated in multiples of 1,000 laser shots for a total of 2,000 shots.

[0305] Size Exclusion Chromatography (SEC): Size exclusion chromatography was performed using a Dionex™ UltiMate™ 3000 HPLC system.

[0306] Unmodified uricase was analyzed by measuring absorbance at 214 nm on a Superose® 12 10 / 300 GL column in 50 mM borate buffer (pH 8) containing 100 mM NaCl at a flow rate of 0.4 mL / min.

[0307] Crosslinked uricase was analyzed by measuring absorbance at 214 nm using two TSKgel® G5000PWXL, 7.8 × 300 mm columns connected in series, with a column temperature of 50°C and a flow rate of 0.3 mL / min in 50 mM Tris buffer (pH 8.0) containing 100 mM NaCl.

[0308] Uricase activity assay: The specific activity of uricase was measured by an indirect fluorometric assay, which detects the HO by-product released after the oxidation of uric acid by uricase. Specifically, 400 μM uric acid was dissolved and added to a sample containing an unknown uricase concentration in 0.1 M sodium phosphate buffer (pH 7.4) supplemented with 0.1% BSA. At 37°C, in the presence of horseradish peroxidase, a fluorescent probe (Ampliflu™) reacted with HO at a 1:1 stoichiometry to yield a highly fluorescent product with excitation wavelengths of 530–560 nm and emission wavelengths of 590 nm. The increase in fluorescence was recorded for 10 min using a microplate reader, and samples were quantified according to a uricase standard curve.

[0309] To perform Michaelis-Menten analysis, catalytic rates were measured as described above for 60 ng / mL enzyme and increasing uric acid concentrations (uric acid concentrations ranged from 1.56 μM to 200 μM). Kinetic parameters were calculated from substrate (UA) concentration vs. reaction rate (V) plots using GraFit software (Erithacus Software Limited, 2010). One unit (U) of uricase activity was defined as the amount of enzyme required to convert 1 μmol of uric acid to allantoin per minute at 37°C and pH 8.0.

[0310] Optical density (OD): The purified proteins were quantified using a NanoDrop™ 2000 spectrophotometer (Thermo Fisher Scientific Inc.) by measuring the absorbance at 280 nm and the respective extinction coefficients (cm -1 (grams / liter) -1 ) was based on this.

[0311] Example 1 In silico comparison of immunogenicity of uricase amino acid sequences To develop a low-immunogenic uricase, the immunogenicity of each of the 46 uricase sequences was estimated by in silico analysis.

[0312] The ProPred MHC class II binding peptide prediction server was used to predict MHC class II binding regions in the sequences using a quantitative matrix, following the procedure described in [Singh & Raghava, Bioinformatics 2010, 17:1236-1237]. MHC class II 9-mer peptide epitopes were identified from the nine most abundant human alleles (DRB1) covering over 90% of the population. * The sequence of the 9-mer peptides was determined for each of the 9-mer peptides (0101, 0103, 0401, 0701, 0801, 1101, 1301, 1015). Various 9-mer peptides were identified and scored based on deviation from the consensus binding sequence at a 5% threshold.

[0313] Peptides showing greater than 15% similarity to the consensus sequence and predicted to bind to more than three MHC class II alleles were considered immunogenic.

[0314] The main strains are Agrobacterium tumefaciens, Alicyclobacillus mali, Arthrobacter gangotriensis, Arthrobacter globiformis, and Aspergillus flavus, Aspergillus udagawae, Aureobasidium pullulans EXF-150, Bacillus fastidiosus, Bacillus halodurans C-125, Bacillus subtilis str beveridgei, Bactrocera latifrons, Blastomyces dermatitidis, Camelus ferus, Candida utillis, Candidatus Solibacter usitatus, Chlamydomonas reinhardtii, Cicer arietinum (Cicer arietinum), Deinococcus radiodurans, Deinococcus geothermalis, Drechmeria coniospora, Erinaceus europaeus (Escherichia coli ISC56), Galdieria sulphuraria, Glycine max (Shadow), Granulicella tundricola, Kyrpidia tusciae DSM 2912, Magnaporthiopsis poae、Microbacterium sp.zzj4-1, Neonectria ditissima, Nicotiana tabacum (tobacco), Paenibacillus darwinianus, Paenibacillus odorifer, Phaseolus vulgaris (kidney bean), Phialocephala scopiformis, Pseudomonas aeruginosa, Pygoscelis adeliae (Adelie penguin), Rousettus aegyptiacus (Egyptian Rouset fruit bat), Stomoxys calcitrans (barn fly), Terriglobus saanensis, Tolypocladium ophioglossoides, and Tolypocladium ophioglossoides CBS 100239.

[0315] Final candidates were selected based on (i) the number of lysine residues, (ii) the number of predicted immunogenic epitopes, and (iii) the score of the predicted immunogenic epitopes. The following uricases were selected for expression as plant recombinant uricases (PRu) in Nicotiana tabacum BY2 cells: Candida utilis uricase (prU-C) (SEQ ID NO: 1, accession number P78609): (eight T cell epitopes were predicted with a maximum similarity score of 54% to the consensus binding sequence. The amino acid sequence contains 32 Lys residues available for protein modification), and Arthrobacter gangotriensis uricase (prU-G) (SEQ ID NO: 3, accession number EMR00187.1): (Five T cell epitopes are predicted with a maximum similarity score of 42% to the consensus binding sequence. The amino acid sequence contains 12 Lys residues available for protein modification.)

[0316] Uricase prU-G and prU-C were calculated to have significantly lower immunogenicity than the sequences of two clinically approved recombinant uricases, rasburicase and pegloticase. In particular, Aspergillus flavus uricase (prU-A) (SEQ ID NO: 4, Accession No. DB00049) had a maximum similarity score of 68% to the consensus binding sequence and was predicted to have 11 T cell epitopes (and 25 Lys residues available for protein modification), while the pig-baboon chimeric uricase used in pegloticase had a maximum similarity score of 68% to the consensus binding sequence and was predicted to have 19 T cell epitopes (and 30 Lys residues available for protein modification).

[0317] For use as a reference, Aspergillus flavus uricase (prU-A) (SEQ ID NO: 4) was also expressed in Nicotiana tabacum BY2 cells.

[0318] prU-C (SEQ ID NO: 1) contains the peroxisomal targeting signal 1 (PTS1) as a tripeptide (TKL) at its C-terminus [Brocard & Hartig, Biochim Biophys Acta 2006, 1763:1565-1573] and is expressed in peroxisomes. prU-A was also expressed in peroxisomes, whereas prU-G was expressed in the cytoplasm.

[0319] Example 2 Effect of the C250K mutation on uricase Plant recombinant Candida utilis uricase (prU-C, SEQ ID NO: 1), prepared as described in the Materials and Methods section herein above, was observed to undergo polymerization under conventional conditions. It was further observed that dithiothreitol (DTT) inhibited the polymerization of prU-C, suggesting that polymerization involves the formation of disulfide bonds between cysteine ​​residues in multiple uricase molecules.

[0320] Cys250 of prU-C is one of four Cys residues contained in prU-C and has been reported to be dispensable for prU-C activity. Furthermore, comparison with published structures of other uricases (not shown) suggested that Cys250 of prU-C faces outward, and such an orientation may facilitate the formation of intermolecular disulfide bonds.

[0321] Considering the above, we analyzed the immunogenicity of the prU-C C250K mutant (prU-C250K; SEQ ID NO: 2) and expressed it in Nicotiana tabacum BY2 cells as described above. Ten T cell epitopes were predicted with a maximum similarity score of 52% to the consensus binding sequence. Similar to prU-C (SEQ ID NO: 1), prU-C250K (SEQ ID NO: 2) contains the peroxisomal targeting signal 1 (PTS1) as a tripeptide (TKL) at its C-terminus [Brocard & Hartig, Biochim Biophys Acta 2006, 1763:1565-1573] and was expressed in peroxisomes.

[0322] The effect of the C250K point mutation on the storage stability of prU-C was then assessed before or after subjecting the protein to freeze / thaw cycles by storing it overnight at −20°C at a concentration of 0.3 mg / mL (determined by measuring the optical density) in 25 mM Tris (pH 8.4).

[0323] prU-C250K was analyzed before and after freezing by measuring specific activity (quantified by a fluorescent activity assay), the formation of high molecular weight (HMW) molecules (measured by size-exclusion chromatography under native conditions), and by SDS-PAGE under denaturing conditions.

[0324] As shown in Table 3 below, in samples of the prU-C250K mutant, only tetramers were present under native conditions before or after freezing, whereas wild-type prU-C contained 8.4% octamers before freezing and 20.2% octamers and 48.4% high molecular weight (HMW) isoforms after freezing (determined by SEC). As further shown, the C250K mutation did not significantly affect specific activity.

[0325] Similarly, as shown in Figure 2, under denaturing conditions (in the absence of DTT), only the monomeric form of prU-C250K was observed before and after freezing, whereas a portion of wild-type prU-C showed variation as molecular species containing multiple subunits, such as dimers and tetramers (as determined by SDS-PAGE).

[0326] [Table 3]

[0327] These results indicate that the C250K mutation enhances the structural properties of uricase compared to the wild-type sequence such that both activity and the tetrameric structure (eg, not the HMW species) are retained.

[0328] Furthermore, without being bound to any particular theory, it is believed that the additional Lys residue (at position 33) of the C250K mutant may further promote protein modification.

[0329] Example 3 Effect of uricase sequence on stability The stability of different uricase variants (prU-A, prU-C, prU-C250K, and prU-G) under physiologically relevant conditions was compared.

[0330] To evaluate thermal stability, uricase was analyzed by nanodifferential scanning fluorimetry. Specifically, purified protein samples were diluted with PBS to a final concentration of 0.5 mg / mL, and 10 μL of each sample was loaded into a capillary. After placement in the capillary array, the plate was placed in the nanodifferential scanning fluorimetry instrument and gradually heated from 15 to 95 °C at a rate of 1 °C / min (excitation power 28%). The onset of the melting temperature (Tm) (the temperature at which the protein begins to unfold) and the temperature at which 50% of the protein is unfolded were measured by software as the change in fluorescence induced by the conformational change of the protein.

[0331] As shown in Table 4, prU-C and prU-C250K exhibited similar melting point parameters, whereas prU-A melted at a significantly lower temperature.

[0332] These results indicate that prU-C and prU-C250K are more stable than prU-A at physiological temperatures, and that the C250K mutation has little or no effect on thermostability.

[0333] [Table 4]

[0334] To assess stability in human plasma conditions, uricase was diluted in human plasma (ex vivo) at a final concentration of 2 μg / mL and incubated for 4 weeks at 37° C. At the indicated time points, protein stability was quantified by specific activity assay.

[0335] As shown in Figure 3, the unmodified prU-A, prU-C, prU-C250K, and prU-G proteins each gradually lost activity after 4 weeks of incubation in human plasma. prU-A exhibited the greatest stability, while prU-G exhibited the least stability in human plasma. prU-C and prU-C250K exhibited similarly significant stability in physiological matrices, indicating that the C250K mutation has little or no effect on plasma stability.

[0336] Example 4 Effect of PEG cross-linking on uricase To crosslink uricase using polyethylene glycol bisaldehyde (bis-Ald-PEG), various sizes (1 kDa to 10 kDa) of bisaldehyde PEG were added to a solution of 1 mole of uricase in phosphate buffer (pH 8), up to 1,000 moles per mole of uricase. A reducing agent was added to the resulting solution at a final concentration of 25 to 100 mM. The coupling reaction was allowed to proceed overnight, e.g., for at least 10 hours, at room temperature (approximately 23 °C). Free PEG was then removed from the reaction mixture by chromatography and / or ultrafiltration. The effectiveness of crosslinking was assessed by SDS-PAGE, and enzyme activity was measured according to a standard curve of unmodified uricase. The ratio of active protein to total protein (measured by optical density (OD) at 280 nm) was expressed as the percentage of activity retained after the reaction.

[0337] Using the general procedure described above, each of the following experiments was carried out using different uricase variants cross-linked with bis-Ald-PEG of various sizes.

[0338] prU-C was cross-linked with 1000 molar equivalents (relative to the total protein tetramer) of bis-Ald-PEG with molecular weights of 1000 Da, 2000 Da, 5000 Da, and 10,000 Da in the presence of 25 mM 2-picoline borane as a reducing agent.

[0339] As shown in Table 5 below, the crosslinked prU-C retained much of the enzymatic activity of native prU-C.

[0340] [Table 5]

[0341] As shown in Figure 4, native prU-C exhibited a molecular weight of approximately 34 kDa on SDS-PAGE, corresponding to the molecular weight of the protein monomer (i.e., one subunit or tetramer of approximately 136 kDa). The smaller band corresponds to the dimer. In contrast, prU-C cross-linked with 2 kDa PEG exhibited a major band corresponding to approximately 315 kDa, with no bands corresponding to significantly lower molecular weights.

[0342] Because PEG molecules migrate with the mobility of proteins twice their molecular weight, the addition of 90 kDa PEG appears as a 180 kDa protein. Thus, the main band at approximately 315 kDa corresponds to fully cross-linked prU-C tetramers (approximately 136 kDa) modified with approximately 45 molecules of 2 kDa PEG. Furthermore, the absence of bands corresponding to molecular weights lower than that of the tetramer indicates efficient covalent cross-linking without any remaining uncross-linked monomers.

[0343] As further shown in Figure 4, prU-C cross-linked with 1 kDa PEG was associated not only with a strong band corresponding to approximately 42 kDa, representing the PEGylated monomer, but also with bands at approximately 80 kDa, 120 kDa, and 160 kDa, representing the PEGylated dimer, trimer, and tetramer, respectively.

[0344] As further shown in Figure 4, prU-C crosslinked with 5 kDa PEG was associated with multiple bands with 10 kDa increments, corresponding to the increments of one PEG molecule (5 kDa) (because PEG molecules migrate with the mobility of proteins twice their molecular weight), including a faded band just under 55 kDa, corresponding to a single prU-C monomer modified with a single PEG molecule.

[0345] These results indicate that 1 kDa PEG and 5 kDa (or larger) PEGs are significantly less efficient than 2 kDa PEG at cross-linking prU-C monomers to tetramers.

[0346] In another experiment, commercially available uricase A (rasburicase) was cross-linked with 500 molar equivalents of bis-Ald-PEG with molecular weights of 600 Da, 1000 Da, 2000 Da, 3400 Da, 5000 Da, and 10,000 Da using 100 mM NaBHCN as the reducing agent.

[0347] As shown in Figure 5, Rasburicase exhibited a molecular weight of approximately 34 kDa on SDS-PAGE, corresponding to the molecular weight of the protein monomer. Rasburicase reacted with 600 Da PEG exhibited major bands corresponding to the monomer and dimer (approximately 40 kDa and 72 kDa, respectively), as well as weaker bands corresponding to the trimer and tetramer (approximately 130 kDa and 160 kDa, respectively). Rasburicase cross-linked with 1000 Da PEG exhibited a major band corresponding to the tetramer, as well as weaker bands corresponding to the monomer, dimer, and trimer. Rasburicase cross-linked with 5000 Da or 10,000 Da PEG exhibited a smear consistent with the monomer and various numbers of PEG molecules (as described above with respect to Figure 4). Furthermore, as shown in Figure 5, rasburicase cross-linked with 2000 Da or 3400 Da PEG did not show bands corresponding to smaller molecular species, but did show a band corresponding to the PEGylated tetramer.

[0348] These results indicate that cross-linking of rasburicase monomers to tetramers with 2 kDa and 3.4 kDa PEG was efficient, but cross-linking with 1 kDa (or less) or 5 kDa (or more) PEG was inefficient, similar to those obtained with prU-C.

[0349] In another experiment, prU-G was cross-linked with 200 or 1000 molar equivalents of bis-Ald-PEG, with molecular weights of 2000 Da, 3400 Da, and 5000 Da, using NaBH3CN as the reducing agent.

[0350] As shown in Table 6 below, prU-G cross-linked with 2000 Da PEG retained significantly more activity than prU-G cross-linked with 5000 Da or 10,000 Da PEG, and the decrease in activity correlated with the amount of cross-linker used.

[0351] As shown in Figure 6, cross-linking of prU-G resulted in relatively high levels of monomeric molecules (bands corresponding to less than 70 kDa on SDS-PAGE) for all bis-Ald-PEGs tested. Furthermore, reaction with 1000 equivalents of PEG resulted in a higher molecular weight than reaction with 200 equivalents of PEG. Under all conditions tested, prU-G enzyme activity was significantly reduced.

[0352] These results indicate that partial cross-linking of prU-G is dependent on PEG concentration and is less efficient than cross-linking of prU-A and prU-C.

[0353] As can be seen, cross-linking of prU-G with 5000 Da PEG was less efficient than cross-linking with 2000 Da or 3400 Da PEG, a result consistent with that obtained with prU-C and prU-A.

[0354] [Table 6]

[0355] Taken together, the above results indicate that uricase cross-linking is most efficient with PEGs greater than 1 kDa and less than 5 kDa, and that cross-linking of some uricase variants (e.g., other than prU-G) under such conditions can yield cross-linked uricase with at least about 50% of the enzymatic activity of unmodified uricase.

[0356] Example 5 Effect of the type of cross-linker on modified uricase Cross-linking of uricase with various cross-linking agents was compared.

[0357] prU-A was crosslinked by reacting with 1000 equivalents of bis-NHS-PEG (2000 Da) in 100 mM phosphate buffer (pH 8) at room temperature for 2 hours, followed by dialysis against 100 mM phosphate buffer (pH 7.4). prU-A was further crosslinked by reacting with 1000 equivalents of bis-Ald-PEG (2000 Da) as described above. 100 mM NaBH3CN was used as a reducing agent. Protein concentration and enzyme activity were measured according to the procedures described above, and crosslinking efficiency and degree of modification were evaluated using SDS-PAGE as described above.

[0358] As shown in Figure 7, both bis-NHS-PEG (2000 Da) and bis-Ald-PEG (2000 Da) resulted in efficient cross-linking of prU-A as determined by SDS-PAGE. The cross-linked prU-A was primarily in the form of a tetramer, and no band corresponding to the non-cross-linked species (<140 kDa) was observed. As further shown in Figure 7, modification with bis-NHS-PEG resulted in a slightly smaller molecular weight compared to modification with bis-Ald-PEG, indicating that fewer PEG molecules were attached to prU-A with bis-NHS-PEG.

[0359] The modified prU-A obtained using both bis-NHS-PEG (2000 Da) and bis-Ald-PEG (2000 Da) retained 59% and 78% of the initial enzyme activity, respectively, when measured as the ratio of protein activity to total protein content (measured by OD at 280 nm).

[0360] These results indicate that the use of aldehyde functional groups and reducing agents is particularly effective for cross-linking uricase in terms of the number of PEG moieties introduced.

[0361] Example 6 Effect of uricase modification on immunogenicity The relative immunogenicity of prU-A crosslinked with either bis-NHS-PEG or bis-Ald-PEG was tested in animal studies according to the procedures described in Example 5. Samples of modified prU-A were mixed with Imject™ alum adjuvant in a 1:1 ratio and injected subcutaneously into 6- to 8-week-old female Sprague Dawley rats (six per group) at a dose of 1 mg (measured by OD) / kg every 3 weeks, as shown in Figure 8A. Serum was collected from each rat at the indicated time points, and titers against the test article (separately for each rat) were measured by ELISA.

[0362] As shown in Figure 8B, immunization with prU-A cross-linked with bis-Ald-PEG (2000 Da) resulted in significantly lower antibody titers compared to prU-A cross-linked with bis-NHS-PEG (2000 Da). As further shown in Figure 8B, repeated injections generally resulted in increased antibody titers.

[0363] The nature of the antibodies generated against cross-linked uricase was examined using a competitive ELISA. Samples were preincubated with unmodified uricase or uricase cross-linked with bis-NHS-PEG or bis-Ald-PEG (2000 Da), and the ability of competitors to inhibit the binding of the generated antibodies was assessed by ELISA.

[0364] As shown in Figures 9A and 9B, antibodies raised by immunization with prU-A cross-linked with bis-NHS-PEG were not inhibited by unmodified uricase, indicating that the antibodies recognized the PEG moiety (Figure 9B). In contrast, antibodies raised by immunization with prU-A cross-linked with bis-Ald-PEG tended to recognize the core protein (Figure 9A).

[0365] Taken together, the above results indicate that cross-linking using aldehyde groups reduces the immunogenicity of cross-linked uricase more effectively than cross-linking using N-hydroxysuccinimide (NHS) groups, and that the use of NHS groups results in the production of large amounts of antibodies against the linking moiety.

[0366] To further evaluate the effect of PEG molecular weight and uricase variants on immunogenicity, prU-A and prU-C were cross-linked with 2000 Da or 3400 Da bis-Ald-PEG1000 equivalents, respectively, followed by dialysis against 100 mM phosphate buffer (pH 8) and size exclusion chromatography (according to the procedures described in the Materials and Methods section hereinabove) to separate the higher molecular weight forms. The amount of conjugated PEG moieties was assessed by MALDI mass spectrometry (according to the procedures described in the Materials and Methods section hereinabove).

[0367] As shown in Table 7, somewhat more PEG moieties were incorporated into cross-linked prU-C than into cross-linked prU-A.

[0368] These results are consistent with the higher abundance of lysine residues in the sequence of prU-C compared to prU-A.

[0369] [Table 7]

[0370] Cross-linked prU-A and prU-C were mixed 1:1 with Imject™ alum adjuvant and injected subcutaneously into 6- to 8-week-old female Sprague Dawley rats (5 per group) at a dose of 1 mg (measured by OD) / kg every 3 to 4 weeks (using the same timeline as shown in Figure 8A). Serum was collected from each rat at the indicated time points, and titers were measured by ELISA.

[0371] As shown in Figure 10, prU-C cross-linked with bis-Ald-PEG (3400 Da) produced the lowest antibody titers upon immunization compared with cross-linked prU-A or prU-C cross-linked with 2000 Da PEG.

[0372] These results indicate that prU-C is somewhat less immunogenic than prU-A, that the methodology described herein for reducing immunogenicity can be used with different types of uricase, and that cross-linking with approximately 3400 Da PEG is particularly effective in reducing immunogenicity.

[0373] The antigenicity of the modified uricase was evaluated by the level of recognition by pre-existing antibodies in human plasma.

[0374] Human serum samples from each patient (n=102) at various naive states were tested for the presence of anti-PEG antibodies using ELISA (as described in the Materials and Methods section hereinabove). Assays were performed using two PEGylated variants of prU-C250K (prepared according to the procedure described above): prU-C250K crosslinked with bis-Ald-PEG (3400 Da) and prU-C250K PEGylated with monofunctional 10 kDa PEG (similar to pegloticase), with unmodified prU-C250K used for comparison. A standard curve was generated using the chimeric cHu3.3 human anti-PEG IgG1 antibody as a positive control. A positive antibody response was defined as an OD ratio of at least 2 relative to the blank; results for patients showing positive responses are shown in Figure 11.

[0375] As shown in Figure 11, screening of naive human blood samples revealed that 15 of 102 donors (15%) tested had pre-existing antibodies that recognized uricase modified with monofunctional 10 kDa PEG, whereas only 3 of 102 donors (3%) (each included in the aforementioned group of 15 donors) had antibodies that recognized prU-C250K cross-linked with 3400 Da PEG, and the titers of these antibodies were significantly lower. As further shown in Figure 11, 20 of 102 donors (20%) had antibodies that recognized unmodified prU-C250K, but none of these donors had antibodies against prU-C250K cross-linked with 3400 Da PEG.

[0376] These results indicate that the PEG crosslinker efficiently masks the uricase protein and that the PEG moiety (a key source of immunogenicity in PEGylated uricase) is significantly less immunogenic when crosslinked with bis-Ald-PEG (approximately 3400 Da) than when modified with 10 kDa monofunctional PEG (similar to pegloticase).

[0377] To assess plasma stability, prU-C250K cross-linked with 3400 Da PEG was incubated ex vivo at 37°C for 4 weeks at a concentration of 2 μg / mL in human plasma. At the indicated time points, uricase activity was assayed according to the procedure described above.

[0378] As shown in Figure 12, all test batches of prU-C250K cross-linked with 3400 Da PEG retained full activity in human plasma over 28 days.

[0379] These results demonstrate that the exemplary cross-linked prU-C250K is highly stable in human plasma.

[0380] An exemplary uricase (prU-C250K) was concentrated to 4.4 mg / mL using an Amicon® system (15 mL) with a 30 kDa cutoff.

[0381] 40 mg of prU-C250K (10 mL) was diluted with 9.86 mL of 100 mM phosphate buffer (pH 8) and added to a reaction mixture containing 50 μL of 200 mM DTT water, 1006 mg (1000 molar equivalents) of bis-Ald-PEG (3400 Da), and 1 mL of 500 mM 2-picoline borane complex in ethanol, resulting in a final concentration of 2 mg / mL protein and 25 mM 2-picoline borane complex. The reaction mixture was mixed by gentle shaking at room temperature for 17 hours. After the reaction, the sample was injected onto a size-exclusion chromatography column to remove high molecular weight (HMW) species. Fractions containing less than 5% HMW species were combined, dialyzed against 100 mM phosphate buffer (pH 8), and concentrated to 1.5 mg / mL (measured by OD).

[0382] Both cross-linked prU-C250K and unmodified prU-C250K were sterilized with a 0.22 μm filter, aliquoted, and stored at −20°C. Concentration and activity were determined as described above. The number of PEG moieties per uricase tetramer was approximately 37, as determined by MALDI mass spectrometry. The proportion of high molecular weight species (modified octamer) was approximately 2%, as determined by size-exclusion chromatography analysis.

[0383] The absence of endotoxin (<5EU / mL) was confirmed by standard procedures, and the degree of masking of the protein's immunogenicity was measured by competitive ELISA.

[0384] The tested uricase was intravenously injected into 12 6-8 week old female Sprague Dawley rats at a dose of 10 U / kg (1.35 mg (measured by OD) / kg for cross-linked prU-C250K and 1.09 mg (measured by OD) / kg for unmodified prU-C250K) every 2 weeks (injections #1-5). Thereafter, cross-linked prU-C250K was injected into both groups every 4 weeks (injection #6), as shown in Figure 13A. Serum was collected for each group at the indicated time points, and titers were measured.

[0385] As shown in Figure 13B, after five injections of unmodified prU-C250K, elevated anti-prU-C250K titers were observed in four of six test animals.

[0386] In contrast, after six IV injections of prU-C250K cross-linked with 3400 Da PEG, anti-prU-C250K-3400 titers were less than 1:50 in all rats tested (data not shown).

[0387] These results further confirm that cross-linking with exemplary PEG moieties significantly reduces the immunogenicity of uricase.

[0388] Example 7 Effect of uricase cross-linking on pharmacokinetics following repeated administration To evaluate the effect of repeated injections on the pharmacokinetics of crosslinked uricase, rats were intravenously injected with prU-C250K crosslinked with bis-Ald-PEG (3400 Da) according to the same procedure as described hereinabove in Example 6. The half-life (T1 / 2) and area under the curve (AUC) of crosslinked prU-C250K were determined by either ELISA or activity assay after the first and sixth injections.

[0389] As shown in Figures 14A-14D, T after the first injection of cross-linked prU-C250K 1 / 2 was 54 hours as measured by ELISA and 64.8 hours as measured by activity assay, while T after the sixth injection 1 / 2 was 70.5 hours as measured by ELISA and 68.4 hours by activity assay.

[0390] As further shown in Figures 14A-14D, the AUC after the first injection of cross-linked prU-C250K was 61.07 mg / kg, as measured by ELISA. * min / mL, and 65.95 mg as measured by activity assay * min / mL, while after the sixth injection, the AUC was 70.5 mg / mL as measured by ELISA. * min / mL, and 58.5 mg as measured by activity assay * min / mL.

[0391] In contrast, the T of unmodified prU-C250K 1 / 2 The time was less than 1 hour (data not shown).

[0392] These results indicate that cross-linking uricase significantly extends the half-life of uricase in plasma, potentially allowing for sustained therapeutic effects and administration at relatively infrequent intervals.

[0393] These results further demonstrate that repeated exposure to cross-linked prU-C250K did not shorten the relatively long half-life of the modified protein in vivo, further indicating that the low immunogenicity and sustained therapeutic effect of the modified protein can be maintained even after long-term treatment.

[0394] Example 8 Comparison of Exemplary Cross-Linked Uricase with Pegloticase The enzymatic activity of an exemplary crosslinked uricase (prU-C250K crosslinked with bis-Ald-PEG (3400 Da)) and pegloticase was compared using the uricase assay and Michaelis-Menten analysis, as described in the Materials and Methods section above.

[0395] As shown in Figure 15 and Table 8, the cross-linked uricase exhibited a significantly higher specific activity, k cat and V max showed.

[0396] [Table 8]

[0397] These results suggest that at high uric acid concentrations (e.g., 200–400 μM, which is expected to be the clinically relevant concentration range of uric acid), the enzyme reaction rate is k cat (and V max ), cross-linked uricase is approximately 5 times more effective than pegloticase, at low concentrations approaching 30 μM (K for pegloticase). M ), cross-linked uricase was more than twice as effective as pegloticase, with an enzymatic reaction rate of k cat / K M These results show that cross-linked uricase is slightly more effective than pegloticase even at very low uric acid concentrations, which are roughly proportional to the uric acid concentration.

[0398] The in vivo efficacy of cross-linked uricase and pegloticase was also compared by intravenous injection into female Sprague Dawley rats at a dose of 1 mg / kg. Plasma samples were collected after the first injection (naive pharmacokinetics) and after four repeated injections at 3-week intervals (repeated pharmacokinetics), and the plasma half-life was calculated by measuring the active enzyme concentration at each time point.

[0399] As shown in Figures 16-18, the exemplary cross-linked uricase exhibited a longer plasma half-life than pegloticase both after a single dose (Figures 16 and 18) and after repeated (four) doses (Figures 17 and 18).

[0400] Taken together, the above results demonstrate that the enzymatic activity of the cross-linked uricase described herein compares favorably to that of pegloticase both in vitro and in vivo.

[0401] While the present invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications, and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications, and variations that fall within the spirit and broad scope of the appended claims.

[0402] It is the intention of the applicants that all publications, patents, and patent applications mentioned herein be incorporated by reference in their entirety as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference herein. In addition, citation or identification of any reference in this application should not be construed as an admission that such reference is available as prior art to the present invention. To the extent that section headings are used, such headings should not be construed as necessarily limiting. Furthermore, any priority document of this application is incorporated herein by reference in its entirety. [Sequence List Free Text]

[0403] SEQ ID NO: 2: Point mutation C250K of SEQ ID NO: 1

Claims

1. A modified uricase comprising a uricase polypeptide crosslinked by at least one bifunctional linking moiety comprising a poly(alkylene glycol) moiety, said bifunctional linking moiety having a molecular weight in the range of 1.5 kDa±10% to 4 kDa±10%.

2. 2. The modified uricase of claim 1, wherein the molecular weight of the bifunctional linking moiety is in the range of 2 kDa±10% to 3.5 kDa±10%.

3. The modified uricase of claim 1 , wherein the uricase polypeptide is bound to an average of at least eight of the bifunctional linking moieties.

4. The modified uricase of claim 1 , wherein at least 30% of the lysine residue side chains in the modified uricase are covalently attached to the at least one bifunctional linking moiety.

5. The modified uricase of claim 1, wherein the bifunctional linking moiety is represented by Formula I: -CH 2 -L 1 -[O-(CH 2 ) m]n-O-L 2 -CH 2 - Formula I (In the formula, L 1 and L 2 are each independently a hydrocarbon moiety or absent; m is an integer ranging from 2 to 10; n is an integer ranging from 2 to 1000.

6. The modified uricase of claim 5, wherein n is in the range of 30 to 100.

7. The modified uricase of claim 1 in the form of a cross-linked tetramer.

8. 2. The modified uricase of claim 1, comprising at least one polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4, and homologs thereof.

9. The modified uricase of claim 1 , wherein the uricase polypeptide is a plant recombinant polypeptide.

10. A modified uricase comprising a plurality of polypeptides having the amino acid sequence of SEQ ID NO:2, said polypeptides being crosslinked by at least one bifunctional linking moiety comprising a poly(alkylene glycol) moiety.

11. The modified uricase of claim 10, wherein each of said polypeptides is bound to an average of at least eight of said bifunctional linking moieties.

12. The modified uricase of claim 10, wherein at least 30% of the lysine residue side chains in the modified uricase are covalently attached to the at least one bifunctional linking moiety.

13. The modified uricase of claim 10, wherein the bifunctional linking moiety is represented by Formula I. -CH 2 -L 1 -[O-(CH 2 ) m]n-O-L 2 -CH 2 - Formula I (In the ceremony L 1 and L 2 are each a hydrocarbon moiety or absent, m is an integer ranging from 2 to 10; n is an integer ranging from 2 to 1000.

14. The modified uricase of claim 13, wherein n is in the range of 30 to 100.

15. The modified uricase of any one of claims 10, wherein the molecular weight of the bifunctional linking moiety is in the range of 1.5 kDa ± 10% to 4 kDa ± 10%.

16. The modified uricase of claim 10 in the form of a tetramer.

17. The modified uricase of claim 10, wherein the polypeptide is a plant recombinant polypeptide.

18. The modified uricase according to any one of claims 1 to 17 for the treatment of diseases or disorders in which uricase activity is beneficial and / or diseases or disorders associated with excess uric acid levels.

19. 20. The modified uricase of claim 18, for use in treating a disease or disorder selected from the group consisting of gout, diabetes, kidney stones, tumor lysis syndrome, hemorrhagic shock, malaria, allergic inflammation, renal dysfunction, viral infection, acute gastroenteritis, placentitis, sterile inflammation, pregnancy complications, multiple sclerosis, inflammatory bowel disease, gastrointestinal infection, and Lesch-Nyhan syndrome.

20. 20. The modified uricase of claim 18 for use in treatment, wherein the treatment comprises administering the modified uricase at least every other week or at least every two weeks.

21. 20. The modified uricase of claim 18 for use in treatment, wherein the treatment comprises administering the modified uricase at a dosage of 8 mg / month or less.

22. A polypeptide having the amino acid sequence of SEQ ID NO:

2.

23. A method for preparing the modified uricase according to any one of claims 1 to 17, comprising the steps of: (a) contacting a polypeptide with a cross-linking agent comprising a poly(alkylene glycol) moiety and at least two aldehyde groups to obtain a conjugate of the polypeptide and the cross-linking agent; and (b) contacting the conjugate with a reducing agent.

24. 24. The method of claim 23, wherein the reducing agent is selected from the group consisting of picoline borane complexes and cyanoborohydrides.

25. A method for reducing the level of uric acid in a medium, comprising contacting the medium with a modified uricase according to any one of claims 1 to 17.